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Defect in mitophagy has been demonstrated to be implicated in the pathogenesis of 
Parkinson's disease. However, little is known about the regulation of mitophagy, 
especially how Parkin is recruited to mitochondria in a PINK1-dependent manner. The 
well-established model suggests that PINK1 accumulates on the outer membrane of 
damaged mitochondria, subsequently recruiting Parkin. Here I show that upon CCCP 
treatment, the accumulation of PINK1 is neither necessary nor sufficient for Parkin 
translocation to mitochondria. Moreover, I found that reactive oxygen species (ROS) 
scavengers failed to rescue CCCP-induced Parkin translocation due to its inefficiency. 
Importantly, PINK1-dependent Parkin translocation to mitochondria can be reversed by 
the treatment of two different ROS scavengers in response to either the CCCP treatment 
or VDAC1 overexpression. In addition, phosphorylation of VDAC1 may be crucial for 
its ubiquitination mediated by Parkin. The role of ubiquitination of VDAC1 is yet to be 
investigated, though it has no impact on execution of mitophagy. Thus, my data 
highlight the importance of the presence rather than the accumulation of PINK1 in 
Parkin recruitment to mitochondria and accentuate the necessity of fine-tuning ROS 
during mitophagy. Also, my findings provide new insights into the role of 
ubiquitination of VDAC1 in mitophagy.  
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Chapter 1 Introduction 
1.1 The background of Parkinson’s disease (PD)  
1.1.1 The clinical features of PD 
PD is the second most common neurodegenerative disorder after Alzheimer’s disease. 
The lifetime risk of developing the disease is 1.5% (Lees et al., 2009). The incidence of 
the disease rises significantly with age. For instance, in Singapore, about 50 in 100,000 
persons between 50 and 59 years of age are afflicted by PD compared to nearly 1,250 in 
100,000 persons above 80 years (Tan et al., 2007). It is highly urgent to address this 
devastating disease for the ageing society. A selective loss of dopaminergic (DA) neurons 
from the pars compacta of the substantia nigra and the formation of Lewy bodies are the 
pathological hallmarks of PD. Clinically, patients manifest motor disabilities including 
rigidity, bradykinesia, impaired balance and resting tremor as well as non-motor 
symptoms, such as cognitive dysfunctions, sleeping disorders. Advanced stage of PD 
compromises work abilities of patients and restricts them to bed, ultimately leading to 
death (Lees et al., 2009).  
 
1.1.2 The molecular basis of pathogenesis in PD 
In the last two decades, linkage studies identified 28 distinct chromosomal regions related 
to PD and 6 genes have been conclusively described to cause monogenic PD so far (Klein 
and Westenberger, 2012). Analysis of these gene products has shed light to our 
understanding of the molecular pathogenesis in PD. Among the causative genes, some of 
them are related to autosomal dominant familial PD, including α-Synuclein and LRRK2. 
Chapter 1 Introduction 
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Others are linked to autosomal recessive familial PD, including parkin, PINK1and DJ-1 
(Klein and Westenberger, 2012). Like other hereditary diseases, it is believed that 
mutations in α-Synuclein and LRRK2 lead to PD by gain of function, imposing 
cytotoxicity to cells. For instance, α-Synuclein has been found to be the major component 
in Lewy body, while mutant form of α-Synuclein accelerated the formation of Lewy 
body-like fibrils in vitro (Conway et al., 1998). Moreover, triplication in a DNA region 
containing α-Synuclein was found to lead to PD, indicating that quantitative changes in 
α-Synuclein may be also harmful to the cells (Singleton et al., 2003). On the other hand, 
mutations in parkin, PINK1 and DJ-1 cause PD by loss of function, depriving cells of 
protective mechanisms conferred by the protein products of these genes. For instance, 
DJ-1 was found to reduce ROS and cell death induced by 6-OHDA in SH-SY5Y cells and 
mesencephalic neurons. In the same study, a recombinant DJ-1 protein was able to 
alleviate the symptoms in a 6-OHDA-induced mouse PD model, while the mutant DJ-1 
failed to confer the protective effects (Inden et al., 2006). However, cytotoxicity has also 
been observed in a Parkin mutant overexpressed model. It was found that transgenic 
Drosophila overexpressing R275W Parkin showed an age-dependent DA neuronal 
degeneration and locomotor deficits. Interestingly, the flies overexpressing the mutant 
displayed a similar phenotype as parkin null flies (Wang et al., 2007a). There were also a 
few reports showing that heterozygous parkin mutations were related to the risk of PD 
(Sun et al., 2006). Therefore, it is possible that the mutations in parkin may exert some 
detrimental effects on cells. Interestingly, a few digenic mutations were found in familial 
PD patients, which further supports that the pathogenesis of PD shares a common 
Chapter 1 Introduction 
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molecular pathway. For instance, mutations in both parkin and PINK1 were found in two 
siblings and one sporadic patient. The onset age of patients carrying both parkin and 
PINK1 mutations was younger than that of patients with the same parkin mutation, 
suggesting that defect of PINK1 exacerbates the damage caused by the mutation in parkin 
(Funayama et al., 2008). Another study showed that digenic mutations in PINK1 and 
DJ-1 caused PD in a family but not the mutation in PINK1 or DJ-1 alone. Furthermore, 
DJ-1 stabilized PINK1, whereas expression of mutant DJ-1 reduced levels of PINK1 in 
cells (Tang et al., 2006). A noteworthy phenotype is that the loss of function or gain of 
function in some of the PD related genes can be rescued by manipulating some other PD 
related genes. On the one hand, supplement of autosomal recessive PD related gene may 
protect cells from cytotoxicity brought by mutations in autosomal dominant PD related 
genes. In a rat model, co-overexpression of Parkin was able to rescue α-synuclein 
overexpression-induced DA neuron loss (Yamada et al., 2005). Moreover, in a 
Drosophila model, co-expression of human Parkin mitigated DA neurodegeneration 
caused by overexpression of LRRK2 G2019S (Ng et al., 2009). In a recent study, 
overexpression of α-synuclein resulted in mitochondrial fragmentation, while 
knockdown of α-synuclein led to mitochondrial elongation. The changes caused by 
α-synuclein were not dependent on mitochondrial fusion and fission machinery, but the 
phenotype resulted from overexpression of α-synuclein could be rescued by 
co-expression of PINK1, Parkin or DJ-1 (Kamp et al., 2010). On the other hand, the 
defects of a particular autosomal recessive PD-related gene may be compensated by 
another autosomal recessive PD-related gene. For instance, Drosophila with parkin or 
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PINK1 mutations shared a similar phenotype. Overexpression of Parkin was able to 
rescue the mitochondrial abnormality in PINK1 mutant flies, but overexpression of 
PINK1 failed to do so in parkin mutant flies, which puts Parkin downstream to PINK1 
(Park et al., 2006). Another study found that expression of PINK1 or parkin was able to 
restore mitochondrial connectivity compromised by depletion of DJ-1. However, 
overexpression of DJ-1 could also rescue the decreased mitochondrial connectivity 
caused by rotenone in either control or PINK1-deficient cells, suggesting that DJ-1 acts in 
a parallel pathway to Parkin/PINK1 (Thomas et al., 2011). Through the studies of these 
causative genes, it has been found that reduced mitochondrial activity, oxidative stress 
and impaired ubiquitin-proteasome activity play a role in the mechanisms for the onset 
and development of PD, which are yet to be further disentangled (Hatano et al., 2009). 
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1. 2 PTEN-induced putative kinase 1 (PINK1), a kinase in PD 
1.2.1 The localization of PINK1  
Among the genes related to PD, parkin and PINK1 have been the hotspots of research. 
PINK1 mutation was first identified to be the cause for an early onset familial PD in 2004 
(Valente et al., 2004). PINK1 has been accepted as a mitochondrial protein, but the debate 
over its precise localization has never stopped mainly because of the low abundance of 
PINK1 protein in cells, which makes the detection of PINK1 by antibody very difficult, 
especially for immunofluorescence study. The first conclusion of PINK1 mitochondrial 
localization was drawn with the employment of c-Myc PINK1 (Valente et al., 2004). 
However, the N-terminal tag later was proven to give a false manifestation, amplifying 
the signal of mitochondrial targeting sequence of PINK1, though the underlying 
mechanism is unknown (Matsuda et al., 2010). Nowadays prevalent studies on PINK1 are 
conducted with the aid of C-terminal tagged PINK1, as the localization of this exogenous 
protein detected is consistent in most of the biochemical studies, which show that PINK1 
localizes in both mitochondria and cytoplasm (Matsuda et al., 2010). However, 
depolarization of mitochondria apparently accumulates PINK1 on mitochondria, which 
seem to be the operational site of PINK1, as overexpression of PINK1 without its 
mitochondrial targeting sequence fails to target PINK1 to mitochondria and recruit Parkin 
to mitochondria, initiating mitophagy (Matsuda et al., 2010; Narendra et al., 2010b). In 
2010, a seminal study of PINK1 localization was accomplished by Jin SM et al., showing 
that PINK1 is imported to the inner mitochondrial membrane and mainly processed by 
the protease, presenilin-associated rhomboid-like (PARL) and then degrade in 
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mitochondria in a mitochondrial potential-dependent manner. The beauty of this story lies 
in the fact that the model successfully explains the reason why Parkin can recognize and 
specifically be recruited to damaged mitochondria observed in many studies (Geisler et 
al., 2010; Matsuda et al., 2010; Narendra et al., 2010b). The accumulation of PINK1 on 
depolarized mitochondria is due to the inability of damaged mitochondria to properly 
process PINK1. In contrast, the healthy mitochondria retain their ability to process 
PINK1 and further degrade it. Thereby, different levels of PINK1 may differentiate 
damaged mitochondria from healthy ones. Subsequently, Parkin may sense the 
differences in mitochondria flagged by PINK1 through an unknown mechanism (Jin et al., 
2010). However, at least two conclusions of their study contradict the observations made 
by the others: one is that they demonstrated that the processed PINK1 localized in inner 
mitochondrial membrane, and postulated that the processed PINK1 was degraded by a 
protease sensitive to proteasome inhibitor. However, previous literature showed that the 
short form of PINK1 also localized in cytoplasm and degraded in proteasome (Beilina et 
al., 2005; Lin and Kang, 2008). Furthermore, one study showed that the cytoplasmic 
PINK1 sufficiently protected cells from the damage caused by a mitochondrial toxin, 
MPP (Haque et al., 2008). But this might be an artificial effect in that to carry out the 
research, both of the studies and most of other studies employed exogenous PINK1, 
which might overwhelm the transporting and/or processing ability of the host cells and 
exaggerate the function of the processed PINK1. It is possible that the processed PINK1 
might just be the intermediate product of the protein degradation, as the processed 
endogenous PINK1 can hardly be detected in biochemical study. The second phenotype 
Chapter 1 Introduction 
14 
 
observed in this particular study but remained to be confirmed is that ectopic PINK1 
expression could recruit Parkin to mitochondrial in a PARL knockout background. 
Contrary to the observation is the study showing that the absence of PARL compromised 
Parkin translocation to mitochondria significantly. In addition, single mutation in PARL 
was found in sporadic PD (Shi et al., 2011). If processing of PINK1 by PARL is 
dispensable for Parkin translocation to mitochondria, what role does PARL play in the 
mechanism of PD? The disparities in these observations undoubtedly add another layer of 
complexity to the already puzzling study of mechanism in PD. It is noteworthy that 
PINK1 can be targeted to different compartments in the cells under different 
circumstances, which makes it possible that PINK1 possesses multiple functions in 
diverse cellular contexts. Upon mitochondrial depolarization, PINK1 accumulates on 
outer mitochondrial membrane (OMM), recruiting Parkin and initiating mitophagy 
(Narendra et al., 2010b). With proteasome inhibition, the processed form of PINK1 
accumulates in the cytoplasm and forms aggregate, which also contains P62, though the 
function of the aggregate has never been explored (Yamano and Youle, 2013). It will be 
interesting to study how PINK1 is involved in the aggregate formation and what role the 
aggregate may have in the scenario of proteasome inhibition.  
 
1.2.2 The protein stability of PINK1 
Although PINK1 is an imperative protein in mitochondrial homeostasis, which is 
manifested by the fact that loss of function of PINK1 leads to PD, the level of PINK1 in 
cells remains very low and the turnover of the protein is rather rapid (Valente et al., 2004). 
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This phenomenon raises a few questions. Firstly, if PINK1 is so important for cells, why 
is the half-life of PINK1 so short? It is understandable that a long-lived protein provides 
safer support for the cells. To maintain a normal level of PINK1, cells have to keep 
producing the protein. However, protein synthesis is vulnerable to the fluctuations in the 
external environment. If the cells suffer serious stress, the whole machinery of protein 
synthesis might be shut down and the production of PINK1 would be discontinued 
(Novoa et al., 2003). Therefore, it is very risky to keep PINK1 at a high rate of turnover. 
Secondly, why do cells keep producing PINK1 and rapidly degrade it? What makes this 
aspect more complicated is the fact that the migration of PINK1 across mitochondria is 
still unclear and degradation of PINK1 may be sequential and spatially specific. Recent 
studies on the function of PARL reported that several mutations around the 
transmembrane domain in PINK1 apparently enhanced the stability of PINK1 by 
reducing the cleavage of the protein or compromising its transportation (Deas et al., 2011; 
Jin et al., 2010). Moreover, the processed form of PINK1 degrades in the cytoplasm 
following an N-end rule, in which specific N-terminal residues of the substrates are 
utilized as degradation determinants to target the substrates for degradation. Once 
processed PINK1 retrotranslocates to cytoplasm, the phenylalanine residue at the N 
terminus of the processed PINK1 functions as a signal for degradation of PINK1 through 
the ubiquitin‐proteasome system (UPS) (Figure 1.1) (Yamano and Youle, 2013). The 
degradation of PINK1 is well regulated, affected not only by the machinery involved in 
the degradation per se, but also by the transportation of the protein. More specifically, 
once imported to mitochondria, PINK1 is processed by the mitochondrial processing 
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peptidase (MPP). If this step does not occur, PINK1 would not be transported to the inner 
mitochondrial membrane, where it is further cleaved by PARL (Deas et al., 2011). 
Similarly, if there is any condition, in which PINK1 is not processed by PARL due to 
defect either in PINK1 or PARL, PINK1 would be accumulated on mitochondria and not 
be released to cytoplasm for further degradation. Protein stability definitely plays a role in 
PINK1-related PD pathogenesis. Though there was no comprehensive study on PINK1 
stability, mutations of L347P and H271Q were found to significantly decrease PINK1 
stability and significantly affected its proper function (Beilina et al., 2005; Narendra et al., 
2010b). However, the increased protein stability of PINK1 doesn’t necessary mean 
healthier mitochondrial function. The abnormality in the processing of PINK1, which 
accumulates excessive PINK1, also compromises mitochondrial function by influencing 
ROS production (Deas et al., 2011).  
 
 
Figure 1.1 Process of PINK1 in mitochondria under distinct circumstances. 
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With the aids of TOM and TIMM23 complexes, the N terminus of newly synthesized 
PINK1 migrates to the inner membrane of healthy mitochondria, where PINK1 was 
sequentially cleaved by MPP and PARL. Subsequently, the cleaved PINK1 is released to 
the cytosol and degraded by proteasome through the N-end rule pathway. On the other 
hand, PINK1 accumulates on the outer membrane of damaged mitochondria, avoiding 
further process by MPP or PARL. (Adapted from Yamano et al., 2013) 
 
1.2.3 The kinase activity of PINK1 
PINK1 is considered as a kinase with a conserved kinase domain, with the spectrum of its 
substrates expanding (Zhou et al., 2008). The best known substrate is Parkin, the E3 
ligase activity of which is activated once phosphorylated by PINK1. The activated Parkin 
then catalyzes K63-linked polyubiquitination of IKKγ and trigger IκB kinase/nuclear 
factor κB (NF-κB) pathway (Sha et al., 2010). The more important consequence of 
phosphorylation of Parkin by PINK1 is that phosphorylated Parkin translocates to 
mitochondria and initiates mitophagy (Kim et al., 2008). Recently, the PINK1-related 
phosphorylation site of Parkin has been mapped. It was demonstrated that upon 
mitochondrial depolarization, PINK1 phosphorylated the Ser65 residue of Parkin, which 
is important for the translocation of Parkin to mitochondria (Kondapalli et al., 2012). 
However, the direct phosphorylation of Parkin by PINK1 is questioned, because it could 
not be reproduced by some researchers (Vives-Bauza and Przedborski, 2011). Moreover, 
a very recent study led by Dr. Richard Youle reported that none of the serine or threonine 
sites on Parkin was indispensable for Parkin recruitment to mitochondria (Kane et al., 
2014). Furthermore, the deletion of the ubiquitin-like (UBL) domain of Parkin, which 
contains the Ser65 residue, had little effect on Parkin translocation to mitochondria (Kane 
et al., 2014). It has been found recently that PINK1 was also able to conduct 
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autophosphorylation. Through protein structure analysis and proteomic study, the Ser228 
and Ser406 of PINK1 were found to be phosphorylated by itself under the circumstance 
of mitochondrial depolarization. Importantly, the phosphorylation of these two sites was 
indispensable for recruitment of Parkin to the damaged mitochondria (Okatsu et al., 
2012). However, whether the mutations of these two sites would affect the kinase activity 
of PINK1 has not been well characterized. Additionally, it is unknown if mutations at 
Ser228 and Ser406 in PINK1 affect its other functions apart from its kinase activity. In 
addition to Parkin, a few other important substrates of PINK1, namely Miro (Wang et al., 
2011b), Mitofusin 2 (Mfn2) (Chen and Dorn, 2013) and ubiquitin (Kane et al., 2014; 
Koyano et al., 2014) have been reported recently. Mitochondrial fusion and fission have a 
significant impact on the cells. Miro is involved in mitochondria dynamics by linking 
mitochondria to microtubule with the aid of Milton and kinesin heavy chain (KHC). Once 
anchored to microtubule, mitochondria can be targeted to the destinations to fulfill their 
functions (Parganlija et al., 2014). It was reported that PINK1 phosphorylated Miro and 
targeted Miro to proteasomal degradation mediated by Parkin. By manipulating protein 
level of Miro, Parkin and PINK1 were able to regulate mitochondrial movement in 
neurons. One of the most significant consequences of this bioprocess is that Parkin and 
PINK1 could sequester damaged mitochondria for subsequent autophagic degradation 
(Wang et al., 2011b). This finding was supported by another study done in Drosophila 
cells. In addition to the observation that PINK1 regulated protein level of Miro, it was 
found that reduction of Miro could rescue the phenotypes caused by PINK1 mutation in 
DA neurons, while overexpression of Miro was adequate to cause loss of DA neurons. 
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However, the phosphorylation of Miro at Ser156 was not observed in Drosophila cells 
(Liu et al., 2012). In mouse cardiomyocyte, Mfn2 was found to be phosphorylated by 
PINK1, while depletion of Mfn2 impeded Parkin translocation to mitochondria. 
Moreover, the Thr111 and Ser442 on Mfn2 were found to be phosphorylated by PINK1, 
which was indispensable for Parkin binding (Chen and Dorn, 2013). Although this study 
provided the first evidence to support the hypothesis that Parkin was anchored to a 
mitochondrial protein modified by PINK1, whether Mfn2 is a universal substrate for 
Parkin remains debatable. In mouse embryonic fibroblasts (MEFs), Parkin translocation 
to mitochondria was not blocked by Mfn1/2 double knockout. In contrast, Mfn1/2 double 
knockout promoted Parkin-mediated mitophagy, as defect in mitochondrial fusion caused 
by Mfn1/2 double knockout led to accumulation of impaired mitochondria. Parkin was 
able to sense the damage of mitochondria and translocate to mitochondria, initiating 
mitophagy to remove the dysfunctional mitochondria (Narendra et al., 2008). Therefore, 
the role of Mfn2 as an anchor protein on mitochondria for Parkin is debatable. Ubiquitin 
was identified as a bone fide substrate for PINK1. Upon CCCP treatment, ubiquitin was 
phosphorylated by PINK1 at Ser65 residue. The phosphorylation of this particular serine 
site may affect the ubiquitin chain linkage, as serine 65 (Ser65) is very close to the K63, 
which is a polyubiquitin chain linkage site. In addition, it was shown in vitro that 
ubiquitin with PINK1-phosphorylated Ser65 was able to activate Parkin, which was 
revealed by the formation of binding of ubiquitin-thioester to Parkin (Kane et al., 2014).  
Another candidate of PINK1 substrates is TNF receptor-associated protein 1 (TRAP1), 
which is involved in the regulation of cytochrome c release (Pridgeon et al., 2007). 
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Cytochrome c release has been regarded as the hallmark of activation of intrinsic 
apoptotic pathway. Once Cytochrome c is discharged to cytoplasm from mitochondria, it 
forms apoptosome and activates caspase family members to trigger apoptosis (Taylor et 
al., 2008). Overexpression of PINK1 is capable to inhibit oxidative stress-induced 
cytochrome c release and cell death by phosphorylating TRAP1. Therefore, the 
suppressed cytochrome c release mediated by PINK1 contributes to the pro-survival 
function of PINK1 (Pridgeon et al., 2007).  
 
Until now, the most important function of PINK1 kinase activity has been considered to 
be related to mitophagy. It was shown that in PINK1 knockout MEFs, Parkin 
translocation to mitochondria was blocked. Furthermore, the kinase dead mutant of 
PINK1 was not able to rescue the phenotype (Matsuda et al., 2010; Narendra et al., 
2010b). The significance of PINK1 in mitophagy has been echoed in neuronal cells and 
induced pluripotent stem cells (iPS cells) as well (Seibler et al., 2011). The role of PINK1 
in mitophagy will be discussed later. 
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1.3 Parkin, an E3 ligase in PD 
1.3.1 The localization of Parkin  
parkin was identified as a PD-related gene in 1998 (Kitada et al., 1998). Parkin mainly 
localizes in cytoplasm under normal condition. Specifically, Parkin was found on the ER 
surface of rat DA neurons where Parkin promoted the ubiquitination of unfolded Pael-R 
(Imai et al., 2002). Upon different stresses, Parkin translocates to distinct organelles to 
exert its functions. For instance, DNA damage is capable to induce Parkin to move to 
nucleus to promote DNA repair (Kao, 2009). Also, Parkin was observed to be recruited to 
mitochondrial genome to eliminate mutant mitochondrial DNA (mtDNA) (Suen et al., 
2010). Moreover, Parkin was shown to enhance mtDNA metabolism and protect 
mitochondrial genome from oxidative stress (Rothfuss et al., 2009). In addition, Parkin 
was found to physically interact with the promoter region of P53 and suppress its 
expression (da Costa et al., 2009). More intriguingly, Parkin has been found to translocate 
to mitochondria to mediate mitophagy, which will be discussed later. 
 
1.3.2 The solubility of Parkin  
The solubility of Parkin is affected by the mutations on either its UBL domain or RING 
finger domains. Hampe et al. showed that decreased solubility of the protein emerged 
concomitantly with increased aggregate formation. Strikingly, most of the mutations 
studied failed to affect the ligase activity of Parkin. In contrast, decreased solubility 
seemed to be the major consequence caused by the mutations, as it confined Parkin from 
migrating to the destined organelles to fulfill its normal functions (Hampe et al., 2006). 
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Moreover, several PD-related stressors, including 1-methyl-4-phenylpyridinium (MPP+), 
rotenone, and dopamine, caused reduction in Parkin solubility and induction of 
intracellular aggregation. The PD related mutations predisposed Parkin to be affected by 
the stressors. The decreased solubility was verified in mouse brain samples after the 
mouse was administered with MPP+. Also, in patient brain samples, the level of insoluble 
Parkin was significantly higher in brain tissues from PD patients than control (Wang et al., 
2005). 
 
1.3.3 The E3 ligase activity of Parkin 
Like most of the proteins with the RING finger domain, Parkin possesses E3 ligase 
activity and is involved in proteasome-related degradation of misfolding protein (Corti et 
al., 2003; Imai et al., 2002). Since one of the pathological hallmarks of PD is the 
formation of Lewy bodies which comprise of protein aggregates, it is understandable that 
most of the early studies on Parkin provided evidence of how Parkin facilitated 
degradation of misfolding proteins and conferred protective effects on cells. For instance, 
Parkin was found to be able to interact and facilitate degradation of P38 through UPS. 
Overexpression of P38 was demonstrated to cause cell death once accumulated in cells 
due to dysfunction of Parkin (Corti et al., 2003). In addition, it was found that Parkin 
bound and ubiquitinated a glycosylated form of α-synuclein (αSp22), while mutant 
Parkin failed to have the same effects on αSp22. The degradation of αSp22 mediated by 
Parkin was further proved by the abnormal accumulation of αSp22 in Parkin mutated PD 
brain (Shimura et al., 2001). However, more and more evidence points Parkin’s role to 
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proteasome-independent functions. For instance, Parkin was found to bind and 
ubiquitinate synphilin-1, which is a binding partner of α-synuclein. Notwithstanding, 
Parkin was not responsible for the degradation of synphilin-1 if the expression ratio of 
parkin to synphilin-1 was not too high. Furthermore, Parkin was found to mediate lysine 
63 (K63) rather than lysine 48 (K48)-linked ubiquitination of synphilin-1 (Lim et al., 
2005). The following attempts have also found that K63-linked ubiquitination is 
prevalent among Parkin-mediated ubiquitination (Henn et al., 2007; Olzmann et al., 2007; 
Sha et al., 2010). Moreover, in neurodegenerative diseases, K63 linked ubiquitination not 
only promotes inclusion formation, but also facilitates the removal of the same via 
autophagy. Therefore, Parkin may protect cells from a variety of stress through both 
proteasome and lysosome-dependent pathway (Figure 1.2) (Lim et al., 2012). In addition, 
as mentioned above, Parkin translocates to nucleus or mitochondria under different 
conditions and functions in a proteasome-independent manner. For instance, Parkin 
translocates to damaged mitochondria and mediates their degradation by autophagy upon 
mitochondrial depolarization. During this process, UPS is widely activated (Chan et al., 
2011). Interestingly, in an in vitro ubiquitination study, the ligase activity was found to be 
compromised in only two out of ten Parkin mutations (Hampe et al., 2006). Though the 
mutations on Parkin might deregulate its E3 ligase activity by affecting the solubility or 
stability, it is possible that the other functions might also be crucial for the well-off of the 
cell.  
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1.3.4 The regulation of E3 ligase activity of Parkin 
Parkin protein harbors a UBL domain at its N terminus followed by three RING finger 
domains (R0-R2 domain), the latter two of which flank an in between RING (IBR) 
domain (Cookson and Bandmann, 2010). The UBL domain is considered to be 
responsible for Parkin binding directly to proteasome and facilitate to link substrates of 
Parkin to proteasome for degradation (Sakata et al., 2003). Moreover, the UBL domain of 
Parkin can regulate its E3 ligase activity (Chaugule et al., 2011). Both the deletion of 
UBL domain and the pathological mutations, such as K27N and R33Q, could relieve its 
E3 ligase activity from an auto-inhibition state. Moreover, it was demonstrated that any 
tag right in front of the UBL enhanced Parkin E3 ligase activity, which calls on a caution 
when studies of Parkin are carried out using a tagged Parkin (Burchell et al., 2012). The 
enhanced E3 ligase activity may not only promote indiscriminate modification of its 
substrates, but also boost autoubiquitination and lead to its degradation. It would be 
interesting to clarify after Parkin migrates to mitochondria upon the treatment of carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP), if the increase in Parkin E3 ligase activity is 
also regulated by the post-translational modification (PTM) of the UBL, particularly if 
this modification is posed by PINK1. It has been shown that Ser65 might be important for 
Parkin translocation to mitochondria. Though the phosphorylation of Ser65 was well 
established, it has been found that the phospho-mimetic mutation of Parkin, S65E, did not 
automatically target Parkin to mitochondria (Kondapalli et al., 2012).  
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Ubiquitination is an important post-translational modification achieved by synergistic 
action of three classes of proteins: ubiquitin-activating enzymes (E1s), 
ubiquitin-conjugating enzymes (E2s, also referred to as ubiquitin carrier proteins or 
UBCs), and ubiquitin-protein ligases (E3s). E1s activate ubiquitin by linking C-terminal 
carboxyl group to the active-site cysteine of E1, which forms a high-energy thioester 
linkage. Subsequently, the ubiquitin is passed by E1 to the active cysteine of E2. In the 
meantime, E3 ligase helps to recruit a specific substrate and connect it with E2. 
Eventually, the ubiquitin is transferred from E2 to the substrate with the aid of E3. There 
are at least two types of the single unit E3 ligases, namely really interesting new gene 
(RING) and homologous to the E6AP carboxyl terminus (HECT) E3 ligases. For the 
HECT E3 ligase, there is a formation of thioester intermediate of cysteine of the E3, 
during which E2 passes the ubiquitin to E3 before the ubiquitin is delivered to the 
substrate. Therefore, the HECT E3 not only dictates the specificity of a substrate, but also 
directly contributes to the transfer of ubiquitin. In contrast, there is no formation of 
thioester intermediate for RING E3 ligase, E2 directly transfers ubiquitin to the substrate 
(Metzger et al., 2012). As mentioned earlier, Parkin harbors three RING finger domains 
and has been considered as a RING E3 ligase. However, a recent study revealed that some 
E3s with two RING finger domains, including Parkin, may actually function through a 
thioester intermediate in a manner similar to HECTs (Wenzel et al., 2011). A recent study 
showed that the Cys431 residue of Parkin, which is at the conserved position of cysteine 
in human homolog of Ariadne (HHARI) that forms a thioester linkage with ubiquitin, is 
important for the PINK1-independent Parkin E3 ligase activity. Furthermore, it was 
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shown that although C431S of Parkin was able to form an oxyester intermediate, the 
mutation impeded Parkin from translocating to mitochondria and ubiquitinating 
mitochondrial substrates, indicating that the HECT-like ubiquitination of Parkin is pivotal 
for both Parkin recruitment to mitochondria and mitophagy induction (Lazarou et al., 
2013). Moreover, Parkin can act as part of a Skp1–Cul1–F-box (SCF) like ubiquitin 
ligase complex, by interaction with F-box/WD repeat protein hSel-10 and Cullin-1. 
Typically, an SCF E3 ligase complex contains S-phase kinase-associated protein 1 
(SKP1), the E3 ligase RBX1 and cullin 1, as well as an F‑box protein that targets a 
specific substrate for ubiquitination. All of the components in the complex are invariable, 
except the F-box protein, which recognizes and interacts with distinct substrates to confer 
selectivity on the complex. Though immunoprecipitation assay demonstrated that Parkin 
physically interacted with Cullin-1 and F-box protein hSel-10, neither SKP nor the E3 
ligase RBX1 was found in the Parkin involved complex. Hence, Parkin forms a 
Parkin-hSel-10-Cul1 complex to ubiquitinate cyclin E and facilitate its degradation. Loss 
of Parkin led to accumulation of cyclin E in the primary neurons and sensitized midbrain 
neurons to kainate excititoxicity (Staropoli et al., 2003). In summary, Parkin may 
function either as a single unit E3 ligase or through an E3 ligase complex. Therefore, it is 
tempting to postulate that Parkin may possess multiple biological functions in cells. 
 




Figure 1.2 Multifunctional Parkin involved in ubiquitin-proteasome and 
autophagy pathways.  
Parkin can mediate K48 and K63 linked ubiquitination, as well as monoubiquitination. 
Upon a variety of stresses, proteins may undergo misfolding and lose its proper function, 
which can be handled by Parkin. On the on hand, Parkin may target misfolded protein to 
proteasome for degradation. On the other hand, Parkin may catalyze K63 linked 
ubiquitination of misfolded or aggregated protein, followed by autophagic clearance. 
(Adapted from Lim et al., 2012) 
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1.4 Parkin/PINK1-mediated mitophagy 
1.4.1 The role of Parkin/PINK1 in mitochondrial quality control 
Quality control is omnipresent in the organism at every level from the protein to the 
whole organism (Narendra et al., 2012). In a cell, there are chaperone proteins to help 
refold misfolded proteins to repair the damage caused to the proteins. However, if the 
damage is too severe, it is pivotal for the cell to remove damaged and dysfunctional 
proteins, while replenish intact and healthy proteins to maintain the homeostasis of the 
cell. The removal of damaged proteins has more significance than discarding the junk in 
the cell. If the damaged proteins are not eliminated, they may not only lose their original 
functions but also bring about certain cytotoxicity to the cell. For organelles, it is also 
very important for the cell to have a sophisticated system to maintain their health. When 
damage occurs to the organelle, the first defense strategy used is to attempt to correct the 
impairment by repairing the components on the organelle. If the damage is beyond repair, 
the whole organelle would be degraded and new organelle has to be produced to 
compensate for the loss. Accumulating evidence from studies of mutations in familial PD 
related genes, parkin and PINK1, indicates that dysfunction of mitochondrial quality 
control contributes to the pathogenesis of PD. Firstly, Parkin and PINK1 were found to 
promote mitochondrial biogenesis to replenish the pool of healthy mitochondria (Gegg et 
al., 2009; Kuroda et al., 2006). Parkin, the cytosolic E3 ligase, can localize on the 
mitochondria in proliferating cells and promote mitochondrial transcription factor A 
(TFAM) mediated mitochondrial transcription. In addition, Parkin directs the protein 
PARIS (Also known as ZNF746) to proteasomal degradation, thereby promoting 
Chapter 1 Introduction 
29 
 
mitochondrial biogenesis mediated by peroxisome proliferator-activated receptor γ 
coactivator-1α (PGC-1α), which otherwise would be suppressed by PARIS (Shin et al., 
2011). Secondly, Parkin directly binds mtDNA and maintains mtDNA integrity by 
boosting mtDNA repair upon oxidative damage (Rothfuss et al., 2009). Thirdly, proper 
function of Parkin and PINK1 plays an important role in mitochondrial dynamics. Mfn1/2 
(Tanaka et al., 2010) and Drp1 (Wang et al., 2011a), which possess opposite functions 
during mitochondrial fusion and fission, have been identified as substrates of Parkin. 
Different degradation patterns of these mitochondrial dynamics machinery proteins in 
different cellular contexts might explain why loss of Parkin or PINK1 function leads to 
fragmentation of mitochondrial network in mammalian cells, while mitochondria exhibit 
an elongated network in Drosophila cells (Corti et al., 2011). As a result, the altered 
mitochondrial dynamics can impose detrimental effects on cells. Parkin and PINK1 may 
also synergistically regulate the degradation of Miro protein. Degradation of Miro helps 
to sequester unwanted mitochondria and facilitates their autophagic elimination (Wang et 
al., 2011b). Recently, Parkin and PINK1 have been demonstrated to mediate degradation 
of impaired mitochondrial proteins. When mitochondrial potential collapses, Parkin 
redistributes to the impaired mitochondria and ubiquitinates the proteins on the OMM, 
triggering their degradation by proteasome. PINK1 and Parkin may also promote 
biogenesis of mitochondria-derived vesicles (MDV), which transport damaged proteins 
to lysosomes for degradation (McLelland et al., 2014). 
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1.4.2 Proposed models in Parkin/PINK1-mediated mitophagy  
Parkin and PINK1 had been considered as two unique players that were separately 
involved in the pathogenesis of PD until two back to back independent studies published 
in the Nature (Clark et al., 2006; Park et al., 2006). They found that flies defective in 
PINK1 shared the same phenotypes as that in parkin mutant. The phenotypes included 
male sterility, apoptotic muscle degeneration and defects in mitochondrial morphology. 
Besides, double silencing of PINK1 and parkin function gave the phenotypes identical to 
those in either single mutant. Interestingly, overexpression of Parkin was able to rescue 
the phenotypes caused by loss of PINK1 function, but not vice versa. In 2008, another 
seminal study showed that upon mitochondrial depolarization, Parkin was recruited to 
mitochondria, triggering the autophagic removal of mitochondria (mitophagy) (Narendra 
et al., 2008). In 2010, a few independent groups published their discovery that PINK1 
was indispensable for the translocation of Parkin to mitochondria (Geisler et al., 2010; 
Matsuda et al., 2010; Narendra et al., 2010b; Ziviani et al., 2010), even though how 
PINK1 recruits Parkin to mitochondrial remains unclear. Taken together, these studies 
have marked the beginning of the era of mitochondrial quality control in the PD study.  
 
The underlying molecular mechanism of how Parkin/PINK1mediate mitophagy remains 
to be further elucidated. More specifically, how does PINK1 recruit Parkin to 
mitochondria? PINK1 might directly phosphorylate Parkin upon certain stress and target 
Parkin to the organelle. Parkin was repeatedly demonstrated to physically interact with 
PINK1. Moreover, the Thr175 and Thr217 residues in Parkin could be phosphorylated by 
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PINK1 (Kim et al., 2008; Sha et al., 2010). The phospho-deficient mutations of these two 
sites abrogated the translocation of Parkin. However, this hypothesis was challenged by 
the fact that the phospho-mimetic mutations in these two sites failed to automatically 
target Parkin to mitochondria. Furthermore, the mutations might significantly alter the 
structure or the solubility of Parkin (Narendra et al., 2010b). The Ser65 residue of Parkin 
was recently found to be phosphorylated by PINK1. However, as discussed above, its 
importance in Parkin recruitment during mitophagy remains questionable (Kane et al., 
2014). One remaining question is how phosphorylated Parkin is capable to differentiate 
the damaged mitochondria from the healthy ones and exclusively redistributes to the 
impaired ones if there is no extra “tag” labeling the damaged mitochondria. Another 
possible scenario to explain how Parkin is recruited by PINK1 is that there is direct 
interaction between Parkin and PINK1. It has been repeatedly reported that there is 
physical interaction between these two molecules. In one study, both in vitro and in vivo 
data showed that Parkin, PINK1 and DJ-1 could form a complex. Parkin-mediated 
degradation of heat shock-induced misfolded protein was increased by overexpression of 
PINK1 (Xiong et al., 2009). However, a study utilizing size exclusion chromatography 
showed that Parkin and PINK1 were not collected in the same fraction, which indicates 
that these two molecules are not in an identical native complex (Thomas et al., 2011). 
Another study echoed the idea, revealing that Parkin and PINK1 migrated in different 
complexes on the blue native gel (Lazarou et al., 2012). A previous study supporting the 
interaction may not play an essential role in PINK1-dependent Parkin translocation to 
mitochondria is that the mutations on Parkin/PINK1 which compromised Parkin from 
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being recruited to mitochondria had little effect on their interaction (Sha et al., 2010). A 
recent study added an additional layer of complexity to the PINK1-dependent Parkin 
translocation to mitochondria, demonstrating that the processed form of PINK1 localized 
in cytoplasm and bound Parkin, blocking it from targeting to mitochondria (Fedorowicz 
et al., 2014).  
 
Other possible models include that PINK1 is activated by stress and phosphorylates 
certain substrates, causing their conformational changes and thereby providing specific 
motif that is recognized by Parkin. This hypothesis makes sense in a way that Parkin 
participates to from an SCF-like ubiquitin ligase complex, which usually mediates 
phosphorylation-dependent ubiquitination (Staropoli et al., 2003). It was identified that 
Parkin ubiquitinated cyclin E and led to its degradation through an SCF-like ubiquitin 
ligase complex. Therefore, it is possible that the SCF-like ubiquitin ligase complex or 
other SCF complexes which Parkin participates to form also facilitate to recognize the 
motif presented upon mitochondrial depolarization. If this is the case, which proteins 
contribute to the formation of the ligase complex? Which proteins on the mitochondria 
serve as the “bait”, alluring Parkin to translocate to mitochondria? It would be interesting 
to study if the ligase complex involved in cyclin E degradation plays a role in mitophagy. 
In addition, the promising candidates of mitochondrial substrates for Parkin should come 
from the list of proteins that are ubiquitinatied by Parkin during mitophagy. At least three 
of such mammalian substrates have been found: Mfn1, Mfn2 and VDAC1. Mfn1 or Mfn2 
seems not to be the right one as knockout of Mfn1/2 failed to impede mitophagy (Tanaka 
Chapter 1 Introduction 
33 
 
et al., 2010). The observation that Mfn1/2 was not necessary for mitophagy is reasonable, 
as ubiquitination of Mfn1/2 and their further degradation in a proteasome-dependent way 
fit in the model that fragmentation of mitochondria promotes the segregation of damaged 
mitochondria and prevents those mitochondria from remerging into the healthy ones, 
thereby facilitating the following mitophagy (Twig et al., 2008). On the other hand, 
studies of VDAC1 were rather controversial. It was shown that short interfering RNA 
(siRNA)-induced VDAC1 inhibited both Parkin translocation to mitochondria and 
mitophagy execution (Geisler et al., 2010). Following this study, a model was established 
that after being ubiquitinated by Parkin, VDAC1 could be recognized by P62 and/or 
HDAC6, which also recruited phagophore, thereby initiating mitophagy (Figure 1.3) (de 
Vries and Przedborski, 2013; Scherz-Shouval and Elazar, 2011). However, a subsequent 
study doubted this model by demonstrating that VDAC1/3 double knockout had no effect 
on Parkin translocation to mitochondria (Narendra et al., 2010a). It is possible that 
VDAC1 does have a role in recruiting Parkin to mitochondria, but there are other 
redundant proteins to ensure the proper proceeding of mitophagy in case of any accident 
hampering the pivotal cellular protective mechanism. Besides, there was only one siRNA 
applied in the study showing VDAC1 was necessary for mitophagy, which might lead to 
off-target effects by eliminating other substrates of Parkin, such as VDAC2 (Geisler et al., 
2010). A recent study supports this hypothesis, showing that the depletion of VDAC2 in 
VDAC1/3 double knockout MEFs did abolish Parkin recruitment to mitochondria, which 
indicates that the VDAC family members may play a key role in Parkin translocation 
(Sun et al., 2012). However, what is the role of PINK1 in the VDAC family member 
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mediated Parkin translocation to mitochondria? It is tempting to postulate that PINK1 
phosphorylates VDAC, causing conformational change in VDAC. Subsequently, Parkin 
is able to recognize phosphorylated VDAC and is recruited by VDAC.  
  
 
Figure 1.3 Proposed mechanisms by which Parkin and PINK1 are involved in 
mitophagy.  
Parkin ubiquitinates PINK1 phosphorylated Mfn1/2, leading to their degradation, which 
segregates damaged mitochondria and facilitates their removal by autophagy. In addition, 
Parkin is able to ubiquitinate and mediate the degradation of Miro in a PINK1 
phosphorylation-dependent manner, resulting in detachment of mitochondria from the 
microtubules and decrease of mitochondrial movement. Moreover, Parkin ubiquitinated 
VDAC1 can be linked to phagophore by P62 and thereby triggering mitophagy. (Adapted 
from de Vries and Przedborski, 2013)  
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1.4.3 Roles of ubiquitination and proteasome in mitophagy 
What is the impact of Parkin-induced ubiquitination on mitophagy? With the progress 
made in the area of organelle autophagy, it emerges that similar to the pathogens invading 
to cells, organelles like mitochondria can be engulfed by autophagosome with the bond 
linking the ubiquitin-coated organelle to LC-3 (a mammalian homologue of yeast 
Autophagy-related protein 8 (Atg8)), which is anchored to the autophagosome inner 
surface (Kirkin et al., 2009). On the other hand, P62 is considered as the adaptor protein 
targeting the doomed mitochondria to autophagosome through binding both ubiquitinated 
proteins on the mitochondria and Atg8/LC3 on the phagophore. However, the role of P62 
in mitophagy is still under debate. Two independent studies showed that P62 was only 
required for mitochondrial aggregating around nucleus. One of the studies even revealed 
that knockdown of P62 reinforced the execution of mitophagy (Narendra et al., 2010a; 
Okatsu et al., 2010). The enhanced mitophagy due to loss of P62 can be partially 
explained by the observation that only dispersed mitochondria could be engulfed by LC-3 
positive structure during mitophagy induced by mitochondrial depolarization (Chan et al., 
2011). However, if P62 is not required for Parkin-mediated mitophagy, which autophagy 
adaptor protein is in charge of linking ubiquitinated mitochondria to phagophore? A 
possible answer is neighbor of BRCA1 gene 1 (NBR1), which shares similar function as 
P62 during autophagy. Though it has been postulated that P62 and NBR1 may play a 
redundant role in mitophagy, there has not been any report confirming the hypothesis. If 
the combinatory loss of P62 and NBR1 has little effect on mitophagy, it would be 
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interesting to review the role of broad ubiquitination of mitochondrial proteins mediated 
by Parkin in mitophagy.  
 
Is proteasome also involved in the mitophagy? Or is proteasomal degradation of certain 
mitochondrial proteins necessary for mitophagy? In a study conducted in fly, loss of 
function in proteasome seemed to have no effect on mitophagy (Ziviani et al., 2010). 
Another study found no inhibition of mitophagy following treatment of proteasome 
inhibitor revealed by electron microscopy (Yoshii et al., 2011). In contrast, proteasome 
inhibitors have been shown to suppress mitophagy by other researchers (Chan et al., 2011; 
Tanaka et al., 2010). It was shown that Mfn1/2 were degraded in a proteasome-dependent 
manner. The degradation of Mfn1/2 facilitated mitophagy by segregating damaged 
mitochondria from fusing to health mitochondrial network. Thereby, proper proteasomal 
function promotes mitophagy by isolating impaired mitochondria. Another study showed 
that following Parkin translocation to mitochondria, there was comprehensive 
ubiquitination of proteins on the OMM. In addition to K63-linked ubiquitination, 
K48-linked ubiquitination was found to be one of the most important manners for 
ubiquitination. Aforementioned, K48-linked ubiquitination targets the substrates to 
proteasomal degradation. Thereby, proteasome functions to promote mitophagy probably 
by deleting unwanted proteins on the surface of mitochondria. Although it is still too early 
to draw a conclusion if proteasome is involved in mitophagy, one phenomenon of note is 
that proteasomal inhibitors also interfere with the processing of PINK1, the role of which 
in mitophagy is still unclear (Jin et al., 2010; Lin and Kang, 2008). Moreover, the 
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accumulation of processed PINK1 by either proteasomal dysfunction or overexpression 
of the processed PINK1 is able to inhibit Parkin translocation to mitochondria by 
physically interacting and holding back Parkin in cytoplasm (Fedorowicz et al., 2014).  
 
1.4.4 The physiological significance of Parkin/PINK1-mediated mitophagy 
As it is proposed that mitophagy acts as a quality control mechanism in cells to eliminate 
damaged mitochondria, Parkin/PINK1-mediated mitophagy is expect to be pro-survival. 
However, the well-established cell model for mitophagy utilizes CCCP to depolarize the 
entire network of mitochondria. In addition, Parkin is overexpressed to make sure that 
Parkin translocates to all the mitochondria and mediates the removal of all (Narendra et 
al., 2008). Therefore, it is questionable whether the autophagic removal of the whole 
mitochondrial system eventually benefits or demolishes the cells, as mitochondria are the 
power stations for the cells, especially for the neurons which require high energy supply. 
Indeed, in the study that established for the first time the autophagic removal of 
mitochondria by Parkin, it was shown that the cells, which lost their mitochondria due to 
execution of mitophagy, failed to survive as well as control cells (Narendra et al., 2008). 
Moreover, like the general autophagy, mitophagy is able to lead to cell death. A recent 
report showed that a treatment using C(18)-pyridinium ceramide or endogenous 
C(18)-ceramide generation promoted targeting of mitochondria to autophagolysosomes 
and inhibited mitochondrial functions, eventually triggering autophagic cell death 
(Sentelle et al., 2012). On the other hand, the mutations of Parkin and PINK1 have been 
identified in cancers, though it is not sure whether the mutations on Parkin and PINK1 are 
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the byproducts of cancer development or the incentives that drive forward tumorigenesis. 
Attempts have been made to elucidate the roles of Parkin and PINK1 in cancers. It was 
shown that ectopic Parkin expression mitigated the proliferation of Parkin-deficient 
breast cancer cells, by arresting cancer cells at the G1-phase (Tay et al., 2010). Another 
explanation is that the mutations of Parkin resulted in inefficient ubiquitination of cyclin 
E, leading to an accumulation of cyclin E, which prompted the cells into the S and G2/M 
phases of the cell cycle (Veeriah et al., 2010). In the end, the errors in cell cycle 
contributed to tumorigenesis. Taken together, comprehensive mitophagy mediated by 
Parkin/PINK1 ultimately compromises cell viability, while mutations in Parkin/PINK1 
may stimulate tumorigenesis, indicating that  Parkin/PINK1-mediated mitophagy may 
act as a strategy for tumor inhibition rather than a pro-survival strategy in cancer 
development.  
 
In addition, the evidence supporting that mitophagy promotes the well-being of cell is 
still lacking and how Parkin/PINK1-mediated mitophagy is involved in PD is still 
unknown. It is interesting to note that Parkin/PINK1-mediated mitophagy has been well 
demonstrated in the cancer derived cell lines, while results of Parkin/PINK1-mediated 
mitophagy in neurons have been mixed. This further supports the above hypothesis that 
the major role of Parkin/PINK1-mediated mitophagy may be fulfilled in cancer 
development. For instance, a study showed that in neurons, mitochondrial depolarization 
failed to induce Parkin translocation to mitochondria, partially due to differences in ATP 
levels between neurons and other cells (Van Laar et al., 2011). However, another study 
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showed that mitophagy did occur in neurons, but at a much lower speed. Furthermore, 
mitochondria with Parkin accumulation were targeted to the somatodendritic regions to 
facilitate degradation by mature lysosome (Cai et al., 2012). The evidence garnered from 
patient samples has been not consistent either. In one study, mutations in PINK1, 
including nonsense (c.1366C>T; p.Q456X) or missense (c.509T>G; p.V170G) mutations 
abolished ability of PINK1 to recruit Parkin to mitochondria, utilizing induced 
pluripotent stem cells (iPSCs) from skin fibroblasts taken from PD patients, which were 
further converted to DA neurons (Seibler et al., 2011). However, a recent report 
employing an engineered plasmid with GFP-mCherry attached to a FIS1 mitochondrial 
targeting sequence showed that in skin fibroblasts from patients, mitophagy was not 
affected by the mutations in Parkin. Moreover, the mitophagy in the skin fibroblasts from 
these patients was executed in a Parkin/PINK1-independent manner (Allen et al., 2013). 
Another doubt about the role of Parkin/PINK1-mediated mitophagy in PD is that the 
ectopic Parkin has been widely used in the study of mitophagy. How important is the 
endogenous Parkin for mitophagy executed in neurons is still unknown. A report even 
showed that endogenous Parkin was ubiquitinated and degraded upon mitochondrial 
depolarization (Rakovic et al., 2013). If endogenous Parkin is eliminated in this context, 
how can it translocate to mitochondria and subsequently trigger mitophagy? Thereby, the 
importance of Parkin/PINK1- mediated mitophagy in the pathogenesis of PD is still 
debatable. 
  




1.5.1 ROS generation 
These are three kinds of ROS, namely the superoxide anion (O2
-
), hydrogen peroxide 
(H2O2) and the hydroxyl radical (HO
·
) (Murphy, 2009). Mitochondria have been found to 
be the major compartment of ROS production. Under most circumstances, O2 is offered 
with four electrons at the complex IV to yield H2O. However, a small amount of O2 
captures a single electron at proximal sites in the respiratory chain with the aid of reduced 





 is released into the matrix where they can interact with lipids, proteins, 
or DNA (Murphy, 2009). The steady-state concentration of O2
-
 is very low, because it 
either rapidly reacts with its substrate, iron-sulphur ([Fe–S]), or is converted to H2O2 by 
superoxide-dismutase. H2O2 is not a potent oxidant which only mildly reacts with [Fe–S]. 
In contrast, its reductive production, HO
·
 has robust reactivity. O2
-
 may be transported to 
cytoplasm via VDAC1 formed channel, while H2O2 may be released to cytoplasm 
through direct penetration of the mitochondrial membrane (Bienert et al., 2006).  
 
Contrary to the canonical notion that ROS are the byproducts of aerobic respiration, the 
production of H2O2 by membrane-bound NADPH oxidases can be mediated by 
ligand-mediated activation of receptor kinases (Bedard and Krause, 2007). In addition, 
growth factor stimulation causes rapid burst of intracellular H2O2. In turn, H2O2 regulates 
downstream pathways by reacting with specific protein targets through oxidative 
modification of key cysteine residues in the targets. Thereby, ROS can act as a secondary 
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messenger in the signaling transduction pathway (Truong and Carroll, 2013). For 
instance, the stimulation of epidermoid carcinoma cells with EGF resulted in an increase 
in the intracellular concentration of H2O2. Moreover, inhibition of ROS generation by 
catalase suppressed the EGF-induced tyrosine phosphorylation of a variety of its targets, 
thereby interfering with tyrosine signaling transduction (Bae et al., 1997).  
 
1.5.2 ROS with health and disease  
ROS have profound influence on cell death and survival, largely by affecting two 
important biological events, namely apoptosis and autophagy. Apoptosis has been 
classified to intrinsic and extrinsic apoptosis based on the sources of stressors which 
eventually cause apoptosis. The intrinsic apoptotic pathway is activated by a variety of 
intracellular stressors. The mitochondria are able to sense the stressors, which disturb the 
balance of BCL-2 family members, leading to permeabilization of the OMM. A few of 
pro-apoptotic factors, including cytochrome C, release from the intermembrane space 
(IMS) to the cytoplasm, where cytochrome C binds apoptotic protease-activating factor-1 
(Apaf-1) and turns Apaf-1 into a caspase-activating complex known as apoptosome. The 
apoptosome is able to recruit and activate procaspase-9, which further activates 
downstream effectors, such as caspase-3, and triggers the apoptosis (Taylor et al., 2008). 
The role of ROS in the intrinsic apoptotic pathway has been intensively studied. It was 
found that ROS were involved in almost every step of apoptosis activation. For instance, 
H2O2 was found to trigger dimerization of BCL2-associated X protein (BAX) and 
facilitate its translocation from cytoplasm to mitochondria, where it promoted the 
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mitochondrial outer membrane permeabilization (MOMP) (D'Alessio et al., 2005). 
Although the impact of ROS on cytochrome C remains controversial, a study suggested 
that oxidization of cytochrome c (Fe
3+
) was essential for pro-apoptotic activity (Suto et al., 
2005). Another study showed that the activation of caspase-9 required the oxidation of 
Apaf-1 (Sato et al., 2004). For extrinsic apoptotic pathway, extrinsic ligands bind 
transmembrane death receptors, which transduce intracellular signals that ultimately 
result in the demolition of the whole cell (Taylor et al., 2008). The role ROS in extrinsic 
pathway was less studied, though evidence has been presented for its importance. For 
instance, NADPH oxidase-dependent ROS production was found to be indispensable for 
hyperoxia-dependent activation of the extrinsic apoptosis, as chemical inhibition and 
depletion of the p47 subunit of the oxidase significantly reduced the cell death (Wang et 
al., 2007b).  
 
Autophagy is a tightly controlled cellular event in which a double membrane structure is 
formed and engulfs proteins or even organelles to survive harsh environment. Under 
condition of nutrition depletion, mammalian target of rapamycin (mTOR) signaling 
complex is inhibited, hence relieving suppression of mTOR on ULK1, which contributes 
to the initiation of autophagy. Insulin and other growth factors’ signaling may negatively 
affect autophagy by activating the PI3K-Akt signaling pathway, which is able to activate 
mTOR and deactivate Beclin 1 containing complex (Marino et al., 2014). ROS were 
found to modify a cysteine residue near the catalytic domain of ATG4, thereby activating 
autophagy. In contrast, ROS scavengers blocked the formation of autophagosomes and 
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the ensuring degradation of engulfed proteins (Scherz-Shouval et al., 2007). Moreover, 
Chen et al. elaborated that superoxide is necessary for induction of autophagy (Chen et al., 
2009).  
 
Due to the profound impacts on the signaling transduction pathway and other 
physiological processes, ROS are closely related to human health and diseases. On a 
system level, ROS affect many aspects of human health, including immune function and 
cognitive function (Brieger et al., 2012). For instance, H2O2 can be converted into 
hypochlorous acid which is very potent for microbial killing (Mauch et al., 2007). In 
addition, the autophagy activated by ROS is also an important defense force against 
invasion of germs. The role of ROS in cognitive function was demonstrated by chronic 
granulomatous disease (CGD) patients. The disease is caused by the loss of function in 
NADPH oxidase NOX2 (Jirapongsananuruk et al., 2002). It was found that the patients 
also suffered decreased cognitive function, in addition to recurrent infection (Pao et al., 
2004). On the other hand, ROS have been implicated in numerous diseases. ROS bring 
about devastating DNA damage, including base modifications and rearrangement of 
DNA sequences, thereby triggering tumorigenesis (Waris and Ahsan, 2006). As 
mentioned above, ROS have an important role in immune function, its deficiency also 
compromises function of immune system. Loss function of NOX2 leads to CGD, which 
is presented as defenseless to a variety of microbial invasions (Segal, 1996). Moreover, 
NOX2 has a role in the termination of inflammation; therefore, defect in NOX2 is also 
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related to autoimmune diseases, which is caused by abnormal immune reaction to its own 
antigens (Krause and Bedard, 2008).  
 
1.5.3 ROS and PD 
ROS have been considered to be linked to the pathogenesis of PD due to its profound 
effects on lipids, protein, and DNA. ROS bring about damages to proteins, which were 
demonstrated by the nitration of synuclein and nitrosylation of Parkin. Nitration and 
nitrosylation are protein modifications synergistically caused by ROS and RNS (reactive 
nitrogen species) (Yao et al., 2004). Furthermore, synuclein can be covalently modified 
by 4-hydroxy-2-nonenal, which is produced during oxidation of membrane lipid 
polyunsaturated fatty acids, promoting formation of protofibril, which contributes to PD 
pathogenesis (Qin et al., 2007). Of note, mtDNA defect caused by ROS might result in 
dysfunction of proteins in the electron transport chain, which leads to more ROS 
generation, and further impairment of mtDNA (Wallace, 2010). In mitochondrial quality 
control, ROS might act as a signal to trigger the removal of dysfunctional mitochondrial 
proteins or even the organelle as a whole. Moreover, oxidative stress can induce the 
formation of mitochondria-derived vesicles (MDVs) that specifically direct oxidized 
cargo to lysosomes for degradation (McLelland et al., 2014). During mitophagy, however, 
the role of ROS is still controversial. ROS scavenger has been shown to significantly 
reduce Parkin translocation to mitochondria induced by paraquat (Cocheme and Murphy, 
2008). In addition, CCCP-induced Parkin recruitment has also been found to be reversed 
by ROS scavenger in MEFs, and mouse primary cortical neurons (Thomas et al., 2011). 
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However, a few independent groups showed contradictory results where CCCP-induced 
Parkin recruitment in HeLa cells is refractory to ROS scavengers. These results challenge 
the role of ROS in regulating Parkin translocation to mitochondria (Ding et al., 2010; 
Narendra et al., 2008). 
 
On the other hand, since ROS are considered as a culprit in the pathogenesis of PD, the 
study of PD related genes has been focused on their effects on ROS. It was found that 
changes in gene dosage of α-Synuclein may lead to PD. Consistently, overexpression of 
α-Synuclein increased cellular ROS level and sensitized cells to dopamine-induced cell 
death (Junn and Mouradian, 2002). Moreover, the mutations of α-Synuclein aggravate the 
ROS production in the cells. For instance, expression of A30P or A53T mutant of 
α-Synuclein increased intracellular ROS levels, and enhanced H2O2-induced cell death 
(Jiang et al., 2007). Since Parkin and PINK1 have been found to be crucial for 
mitochondrial integrity, loss of Parkin or PINK1 may lead to outburst of ROS. Indeed, 
knockdown of PINK1 promotes ROS and eventually triggers mitophagy. Interestingly, 
Parkin overexpression enhanced the mitophagy induced by loss of PINK1 (Dagda et al., 
2009). This observation is contradictory to the recent findings that PINK1 plays an 
indispensable role for Parkin translocation to mitochondria and subsequent autophagic 
removal of mitochondria (Narendra et al., 2010b). DJ-1 has been considered that its major 
role is to act as a ROS scavenger (Taira et al., 2004). The levels of DJ-1 decreased 
significantly in left ventricular tissue samples from patients with end-stage heart failure 
compared with normal control patients. In addition, Knockout of DJ-1 in mice showed 
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enhanced vulnerability to oxidative stress and eventually developed heart failure (Billia et 
al., 2013). Furthermore, it was shown that reduction of DJ-1 led to increased 
stress-induced Parkin recruitment and increased mitophagy. The phenotypes were 
rescued by expression of wild-type DJ-1, but not a cysteine-106 mutant with defective 
ROS response (Joselin et al., 2012). These findings suggest that ROS play a role in 
Parkin/PINK1-mediated mitophagy.  
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1.6 VDAC1, an essential protein regulating cell fate 
Voltage-dependent anion channel (VDAC) was first found to be the protein with a pore 
forming activity in an extract from mitochondria (Schein et al., 1976). The name of the 
protein was coined because the channel formed by VDAC is more selective to anion, 
though cations, even including some large cations, such as dopamine can also be 
transmitted through the channel. The three dimensional structure of VDAC1 discloses 
that the pore wall mainly consists of positive residues, which explains the selectivity of 
anions. Responsible for metabolite transport between mitochondria and cytoplasm, 
VDAC1 is considered to be crucial for homeostasis of cellular metabolism 
(Shoshan-Barmatz et al., 2010). 
 
1.6.1 The localization of VDAC1 
VDAC1 is the most prevalent protein in mitochondria, as VDACs account for 
approximately 0.4% of total mitochondrial proteins. VDAC1 is about 10 times and 100 
times abundant more than VDAC2 and VDAC3 respectively (De Pinto et al., 2010). It is 
widely accepted that VDAC1 mainly localizes in the OMM. However, VDAC1 is still 
found in plasma membrane though it has been speculated that a large pore formed by 
VDAC1 in plasma membrane should be detrimental to the cell (Yu et al., 1995). The 
function of VDAC1 in plasma membrane is not clear. In neurons, Plasma membrane 
VDAC1 is involved in the regulation of β-amyloid neurotoxicity (Marin et al., 2007).  
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1.6.2 The 3D structure of VDAC1 
The three dimensional structure of VDAC1 was determined in 2008 (Hiller et al., 2008). 
VDAC1 forms a barrel in the lipid bilayer of the OMM by 19 β-strands with its 
N-terminal helical segment embedded inside of the barrel (Figure 1.4). However, the 
structure is contradictory to the results of many previous biochemical and functional 
studies. The major disparities include that the α Helix was detected by a peptide specific 
antibody. The detection was not expected, as α Helix was embedded in the pore of the 
barrel according to the 3D structure. Therefore, the antibody should not have accessed the 
peptide. Protease treatment also provides evidence that some peptide fragments of 
VDAC1, such as 108-119, could be digested rather than protected by the mitochondrial 
membrane, which is incompatible with the 3D structure. In addition, the orientation of 
VDAC1 in the OMM is inconsistent in the biochemical studies and 3D structure. The 
observation that the antibody recognized FLAG tag in the C terminus of VDAC1 with an 
identical efficiency regardless of the intactness of mitochondria indicates that the C 
terminus of VDAC1 faces to cytoplasm. However, the opposite conclusion was made in 
3D structure of VDAC1 (Colombini, 2009).  




Figure 1.4 3D structure of VDAC1. 
A barrel-like structure with 19 β-strands and N-terminal helical segment is formed by 
VDAC1. The strands β1 and β19 form a parallel β-sheet pairing, with N-terminal 25 
residues constituting a partial α-helical structure that transverses the pore. 
(Shoshan-Barmatz et al., 2010) 
 
1.6.3 The role of VDAC1 in apoptosis 
The functional significance of VDAC1 in apoptosis has long been established. VDAC1 is 
considered as a conserved apoptotic factor, as VDAC1 from different sources is capable 
to trigger apoptosis in diverse cell types (Godbole et al., 2003). VDAC1 plays a role in the 
intrinsic apoptotic pathway by forming permeability transition pore (PTP), which is a 
large multiple protein complex spanning through both inner mitochondrial membrane 
(IMM) and OMM. PTP is formed in apoptosis to allow pro-apoptotic mitochondrial 
proteins to release to cytoplasm (Shoshan-Barmatz et al., 2010). Alternatively, the 
homo-oligomers of VDAC1 might serve as channels for release of pro-apoptotic factors. 
Accumulating evidence has verified formation of homo-oligomers of VDAC1. Using 
cross-linking reagent, Zalk et al. reported that upon apoptotic stress, VDAC1 forms 
dimers, trimmers and even higher oligomers (Zalk et al., 2005). VDAC1 might also form 
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hetro-oligomer channel with Bax for the release of pro-apoptotic factors, as the 
interaction between VDAC1 with Bax has been observed. The interaction was 
compromised by pro-survival factors, HK-1 and HK-2 (Pastorino et al., 2002).  
 
VDAC1 mediates the transportation across the OMM of Ca
2+
, the homeostasis of which 
is crucial for TCA cycle, fatty acid oxidation and so on (Shoshan-Barmatz et al., 2010). It 
is noteworthy that the open state of VDAC1 rather than its close state is of property of 
permeability of Ca
2+
 (Tan and Colombini, 2007). On the other hand, Ca
2+
 has been shown 
to directly bind VDAC1 and regulate the function of VDAC1 channel in the OMM. 
Overload of Ca
2+
 induced opening of the PTP, which led to release of pro-apoptotic 
factors to cytoplasm and ultimately triggered apoptosis (Bathori et al., 2006). As 
mentioned earlier, ROS, which is to be released to cytoplasm, depends on VDAC1 to 
move across the barrier of the OMM. Importantly, the inhibitors of VDAC1 activity 
significantly suppressed ROS-induced apoptosis, suggesting that VDAC1 is a major 
regulator of ROS transportation (Shimizu et al., 2001).  
 
1.6.4 Post-translational modification of VDAC1 
The phosphorylation of VDAC1 has been disclosed to affect its function. It has been 
shown that phosphorylation of VDAC1 by Protein kinase C epsilon (PKCe)  led to the 
inhibition of Ca
2+
-induced PTP opening (Baines et al., 2003). In addition, 
phosphorylation of VDAC1 at Thr51 by glycogen synthase kinase 3beta (GSK3β) has 
been shown to compromise the interaction between VDAC1 and HK- II, while the 
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mutation of Thr51 to alanine was able to abolish the effect. Also, Akt was able to enhance 
the interaction between VDAC1 and HK by phosphorylating GSK3β and reducing its 
kinase activity (Pastorino et al., 2005). Moreover, phosphorylation of Ser12 and Ser103 
sensitized endothelial cells to apoptotic stress caused by endostatin. Overexpression of 
VDAC1 mutant harboring S12A and S104A suppressed PTP opening and caspase-3 
activation (Yuan et al., 2008). Although the phosphorylation regulation of VDAC1 has 
been intensively studied, its physiological roles on apoptosis and other cellular events 
need to be further elucidated. 
 
Ubiquitination of VDAC1 has not been intensively investigated until VDAC1 was 
found to be ubiquitinated in the scenario of mitophagy. Following depolarization of 
mitochondria, VDAC1 was ubiquitinated via K27. The ubiquitination was catalyzed by 
overexpressing functional Parkin (Geisler et al., 2010). Moreover, ubiquitinated 
VDAC1 could be recognized by autophagy adaptor proteins, such as P62 and NBR1. It 
was hypothesized that the autophagy adaptor proteins further recruited phagophore and 
initiated mitophagy. However, the role of ubiquitination of VDAC1 was challenged by 
a study led by Dr. Richard Youle, which revealed that mitophagy in VDAC1/3 double 
knockout MEF cells preceded as smoothly as in wild type cells. (Narendra et al., 2010a). 
Furthermore, ectopically localized PINK1 was capable to recruit Parkin to peroxisomes 
and lysosomes in addition to mitochondria, and subsequently triggered peroxisome 
autophagy, namely pexophagy, indicating that there is no specific mitochondrial protein 
indispensable for either parkin translocation to mitochondria or mitophagy execution 
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(Lazarou et al., 2012). However, depletion of VDACs was able to impede Parkin 
translocation to mitochondria, suggesting that VDAC family members function 
redundantly as mitochondrial adaptor proteins for Parkin translocation (Sun et al., 2012). 
There is also one question about the VDACs as substrates for Parkin: if VDAC2 is able 
to act as a substrate for Parkin on the mitochondria, the E3 ligase activity is not 
indispensable for Parkin translocation to mitochondria, as VDAC2 was not found to be 
ubiquitinated by Parkin. This hypothesis is not consistent with the current finding that 
E3 ligase activity, especially the HECT-like E3 ligase activity of Parkin is crucial for 
Parkin recruitment to mitochondria (Lazarou et al., 2013). Another question is if 
VDAC1 is not directly involved in mitophagy, why VDAC1 is heavily ubiquitinated 
following mitochondrial depolarization? As mentioned above, VDAC1 is involved in 
apoptosis by either contributing to permeability transition pore or forming oligomers. 
Those channels formed in the mitochondrial membrane allow pro-apoptotic proteins to be 
released to activate downstream effectors in cytoplasm. It is possible that the 
ubiquitination of VDAC1 may promote cell survival during mitophagy by facilitating the 
degradation of VDAC1 and blocking the release of pro-apoptotic factors.  
  




Parkin and PINK1 have been identified to mediate the removal of damaged 
mitochondria by autophagy (mitophagy). However, the regulation of the Parkin/ 
PINK1-involved mitophagy is largely unknown. The well-established model of the 
initiation of mitophagy suggests that mitochondrial impairment can accumulate PINK1 
on the outer membrane of dysfunctional mitochondria. Subsequently, Parkin is recruited 
to the affected mitochondria, triggering mitophagy. It has been disclosed that a few 
post-translational modifications drive the cascade forward. For instance, following 
mitochondrial depolarization, PINK1 undergoes autophosphorylation at Ser228 and 
Ser402, resulting in an increase of its capability to recruit Parkin to mitochondria (Okatsu 
et al., 2012). The accumulated PINK1 may activate Parkin by phosphorylating Ser65 
residue (Kondapalli et al., 2012), thereby releasing it from its auto-inhibitory state 
(Chaugule et al., 2011). Alternatively, PINK1 may phosphorylate ubiquitin to activate 
Parkin (Kane et al., 2014; Kazlauskaite et al., 2014; Koyano et al., 2014). Subsequently, 
Parkin translocates to mitochondria, where it is anchored to the mitochondrial substrates, 
such as VDAC1 (Sun et al., 2012) and Mfn2 (Chen and Dorn, 2013). Once anchored to 
mitochondria, Parkin mediates global polyubiquitination of the OMM proteins, triggering 
the convergence of the autophagic machinery to mitochondria to ensure proper execution 
of mitophagy (Chan et al., 2011; Lee et al., 2010).  
 
  




Despite intensive studies on Parkin/PINK1-mediated mitophagy, there are many 
important questions yet to be addressed. For instance, upon mitochondrial dysfunction, 
PINK1 is accumulated and autophosphorylated. Therefore, it would be interesting to 
dissect if both changes are important for the role of PINK1 in mitophagy. Furthermore, it 
is known that CCCP induces depolarization, resulting in Parkin translocation to 
mitochondria. However, CCCP treatment leads to mitochondrial depolarization and 
possibly the production of ROS as well. Therefore, I am interested in understanding 
whether the production of ROS is also responsible for Parkin recruitment. In addition, 
prior to autophagic clearance of mitochondria, Parkin mediates ubiquitination of the 
OMM proteins, including VDAC1. I also would like to address whether ubiquitination of 
VDAC1 is indispensable for mitophagy.  
Based on the current understanding of Parkin/PINK1-mediated mitophagy, my objectives 
of this thesis are:  
1. To study the necessity and adequacy of accumulation of PINK1 in recruiting Parkin 
to mitochondria. 
2. To determine if ROS production is involved in Parkin/PINK1-mediated mitophagy 
by affecting Parkin recruitment. 
3. To investigate the possible role of ubiquitination of VDAC1 in mitophagy. 
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Chapter 2: Materials and methods 
2.1 Gene cloning 
2.1.1 RNA isolation 
Total RNAs was isolated from HEK 293T cells using Trizol reagent (Invitrogen) 
according to manufacturer’s protocol. In detail, 1 ml of Trizol was added to a well of a 
6-well plate of HEK 293T cells. The homogenized cells were incubated at room 
temperature for 5 min to allow nucleoproteins to dissociate before adding 200 μl 
chloroform. The mixture was shaken for 15 seconds and incubated at room temperature 
for 2-3 min, followed by centrifugation at 12,000xg for 15 min at 4°C to separate the 
aqueous and organic phases. 500 μl aqueous phase was transferred to a new tube and 
mixed with 500 μl isopropyl alcohol. The mixture was incubated at room temperature 
for 10 min and centrifugated for 15 min at 12,000xg at 4°C. The supernatant was 
discarded and the pellet RNAs were washed with 70% ethanol and centrifugated at 
7500xg for 5 min at 4°C. The RNA pellet was briefly air dried and dissolved in 20 μl 
Diethyl pyrocarbonate (DEPC) water. The isolated RNAs can be used for downstream 
experiments immediately or be stored at -80°C. 
 
2.1.2 Reverse transcription polymerase chain reaction (RT-PCR) 
The RT-PCR was carried out using SuperScript
TM
 Reverse Transcriptase from 
Invitrogen. Firstly, a mixture of RNA template (11.5 μl ), OligodT (1 μl) and dNTP (1 μl) 
was incubated at 65 °C for 5 min and chilled on ice. Next, 5 X First strand buffer (4 μl), 
0.1 M DTT (2 μl) and RNAas outTM (0.24 μl) were added and incubated for 2 min at 
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42 °C. Subsequently, SuperScript RTase
TM
 (0.25) was added to the mixture and 
incubated for 50 min at 42 °C and 15 min at 70 °C. The synthesized cDNA were used 
for PCR immediately or be stored at -80°C. 
 
2.1.3 Polymerase chain reaction (PCR) 
The gene constructs was amplified by PCR from the cDNA library using DyNAzyme
TM
 
EXT DNA polymerase (Finnzymes, Thermo Scientific). The reaction system adopted 
was shown in Table 2.1. The PCR cycle parameters are shown in Table 2.2. The 
sequences of primers used are shown in Table 2.3. 
 












Component Volume (μl) 
cDNA template (200ng/μl) 1-2 
Forward primer (10 nM) 0.5 
Reverse primer (10 nM) 0.5 
dNTP (10 nM) 0.5 
10 X 514 Buffer 2.5 
DyNAzymeTM EXT 0.5 
Double-distilled water Top up to 25 μl 
Total volume 25 
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Table 2.2 PCR cycle parameters 
 
 
Table 2.3 sequences of primers for cloning 
 
Cycle Step Temperature (°C) Time 
1 Initialization 95 3 min 
 Denaturation 95 30 s 
25 Annealing 55 40 s 
 Extension 72 1 min ( 1min/kb) 
1 Final elongation 72 5 min 
1 Final hold 4 ∞ 
Insert Vector Primer (5’-3’) 
Insertion 
site 
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2.1.4 DNA ligation and transformation 
The pcDNA3-FLAG-Parkin plasmid was generously provided by Dr. Lim Kah Leong 
(Department of Physiology, Faculty of Medicine, and National University of Singapore). 
The PINK1-GFP was obtained from Addgene. The genes amplified from the cDNA 
library or template were purified with QIAquick Gel Extraction Kit (Qiagen) and 
subjected to double restriction enzymatic digestion. The restriction enzymes and buffers 
used in this study were purchased from NEB. The reaction was incubated at 37 °C for 
2-6 hours. The components of restriction digestion reaction were shown in Table 2.4 
 










The digested products were purified again with QIAquick Gel Extraction Kit (Qiagen) 
and inserted into pXJ40 vector (a gift from Dr. Low Boon Chuan, Department of 
Biological Sciences, National University of Singapore) with different tags, including 
Component Volume (μl) 
Purified PCR product 16.5 
Restriction enzyme 1 0.5 
Restriction enzyme 2 0.5 
10 X Buffer 2 
BSA 0.5 
Total volume 20 
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FLAG, BFP and GFP. VDAC1 gene was also inserted into EGFP-N1 vector (Clontech) 
to fuse GFP tag to the C terminus of VDAC1. PINK1 gene was inserted into c-Flag 
pcDNA3 vector (addgene). For construction of BFP-T2A-FLAG-VDAC1 plasmid, T2A 
sequence (GAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAAT 
CCCGGCCCT) was designed upstream of FLAG sequence and ordered as an oligo 
primer for PCR amplification from pXJ40-FLAG-VDAC1 plasmid. SalI restriction 
enzyme site was designed upstream of the T2A sequence to generate compatible sticky 
end with XhoI digested sites. BgIII was designed downstream of the VDAC1 sequence. 
The T2A T2A-FLAG-VDAC1 sequence was amplified by PCR was digested with SalI 
and BglII while pXJ40-BFP vector was linearized with XhoI and BglII restriction enzyme. 
XhoI restriction enzyme site is destroyed following the successful ligation of 
T2A-FLAG-VDAC1 sequence into the pXJ40-BFP vector. The sequences of primers 
used are shown in Table 2.5. 
 
Table 2.5 Sequences of primers for BFP-T2A-FLAG-VDAC1 construction 
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The ligation reaction was incubated at 4 °C overnight. The components added in the 
reaction were shown in Table 2.6. After ligation, the product was transformed into 
DH5α or TOP10 competent cells. The ligation products were added into 100 μl DH5α 
or TOP10 competent cells and incubated on ice for 30 min. Subsequently, the mixture 
was heated at 42 °C for 90 seconds and cooled on ice for 3 min. 1 ml of LB medium 
(Conda) was added into the mixture and incubated at 37 °C shaker for 1 hour. After 
incubation, the mixture was centrifugated and supernatant was removed. The pellet was 
resuspended and were spread and grown on LB agar plate supplemented with 
appropriate antibiotics for around 16 hours and colonies on the plate were picked for 
plasmid extraction. 
 









Plasmid extraction was carried out using miniprep plasmid extraction kit (Axygen) 
according to manufacturer’s protocol. Double restriction enzymatic digestion was 
Component Volume (μl) 
Double digested PCR product 7 
Double digested vector 0.5 
T4 ligase (Promega) 0.5 
10 X  T4 ligase Buffer (Promega) 1 
Total volume 10 
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performed to the plasmids to verify the insertion and the plasmids with insertion were 
subject to DNA sequencing analysis to confirm the fidelity of the inserted segment.  
 
2.1.5 DNA sequencing 
DNA sequencing was carried out using ABI PRISM BIG DYE
TM
 Terminator Cycle 
Sequencing Ready Reaction Kit (Applied Biosystems). The sequencing PCR mixture 
and cycling parameters are shown in Table 2.7 and Table 2.8, respectively. 
 














Component Volume (μl) 
Terminator Ready Reaction Mix 2 
1 mM sequencing primer 3 
5 X  sequencing reaction buffer 4 
Template DNA (200-500 ng/μl) 1 
Double-distilled water 10 
Total volume 20 













The PCR products was mixed with 20 μl of 3 M NaOAc pH 4.6 and 50 μl of 95% 
ethanol and incubated at room temperature for 10 min. The samples were centrifuged at 
13,200 rpm at 4 °C for 10 min. The supernatant was removed and the pellet was washed 
twice with 500 μl of 70% ethanol, centrifuging at 13,200 rpm for 5 min after each wash. 
The pellet of PCR product was air-dried at room temperature and dissolved in 15 μl 
HiDi and subject to automated sequencing on the ABI 377 sequencer system.  
 
2.1.6 Site-directed mutagenesis 
FLAG-VDAC1 single and multiple mutations were carried out by site-directed 
mutagenesis using QuickChange
TM
 Site-Directed Mutagenesis Kit (Stratagene, CA). 
The experiments were performed following the manufacturer’s instruction. The 
components added into the PCR reaction were shown in Table 2.9. The PCR cycle 
Cycle Temperature (°C) Time 
1 95 1 min 
 95 10 s 
25 50 5 s 
 60 1 min  
1 4 ∞ 
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parameters are shown in Table 2.9. 
 
Table 2.9 site-directed mutagenesis PCR reaction system 
Component Volume (μl) 
Template plasmid (50 ng/μl)  1 
Primer forward (10nM)  1 
Primer reverse (10nM)  1 
dNTP (10nM) 1 
10 × buffer  5 
Pfu Turbo DNA polymerase  1 
Sterile distilled water  40 












Chapter 2: Materials and methods 
64 
 
Table 2.10 site-directed mutagenesis PCR cycle parameters 
 
 
2.1.7 Short hairpin RNA (shRNA)-mediated gene knockdown 
For PINK1 knockdown, one target sequence of PINK1 shRNA was adopted from 
Weihofen A et al (Weihofen et al., 2008). Two shRNA sequences were designed using 
Invitrogen website BLOCK-iT
TM
 RNAi Designer. For VDAC1 knockdown, three 
shRNA sequences were designed using Invitrogen website BLOCK-iT
TM
 RNAi Designer. 
The target sequences are shown in Table 2.11. The custom oligos were designed with 
target sequence followed by the sticky ends and hairpin loop region in the middle. The 
oligos were cloned into the pSUPER•puro empty vector according to the manufacturer’s 




Cycle Step Temperature (°C) Time 
1 Initialization 95 1 min 
 Denaturation 95 1 min 
18 Annealing 60 1 min 
 Extension 72 6 min ( 1min/kb) 
1 Final elongation 72 10 min 
1 Final hold 4 ∞ 
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Table 2.11 shRNA sequences targeted to PINK1 












2.2 Cell culture and treatment 
2.2.1 Cell culture 
HeLa and 293T cell line (ATCC) was maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) media with 10% fetal bovine serum and 1% penicillin/streptomycin 
at 37 °C under 5% CO2 conditions.  
 
2.2.2 Transfection 
Transfection was carried out using lipofectamine 2000 (Invitrogen) according to 
manufacturer’s protocol. Cells were seeded into 12-well plates or 6-well plates in the 
morning. Cells reached 60%-70% confluency 8 h later and the medium removed and 
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supplement with fresh non-antibiotics medium. For a 6-well format, 1 μg of the plasmid 
of interest was added into 250 µl of Opti-MEM I media. 5 μl of Lipofectamine 2000 
reagent was diluted into 250 µl of Opti-MEM I media. 5 min later, the diluted plasmid 
and Lipofectamine 2000 reagent were mixed. The transfection mixture was incubated in 
room temperature for another 20 min, followed by adding into cells directly. 4-6 h later, 
medium can be changed. For larger or smaller plates, plasmid DNA and reagents were 
scaled up or down according to the surface area of plates. 
 
2.2.3 Establishment of stable knockdown cell lines  
A kill curve of HeLa cells from our lab for puromycin was established to determine 
optimal concentration for selection of puromycin resistant cells. One day before 
puromycin treatment, cells were seeded in 6 well plates. Next day, 0.5-3.0 µg/ml 
puromycin was added to cells at confluence of 70-80%. 1.0µg/ml puromycin was the 
lowest level that killed all the cells within 5 days. To generate stable PINK1, VDAC1 
knockdown cell lines, HeLa cells were transfected with control shRNA, PINK1 and 
shRNA respectively using Lipofectamine 2000 (Life Technologies) and selected with 
puromycin (1.0 µg ml
-1
) for 21 days.  
 
2.2.4 Treatment 
To stimulate Parkin translocation to the mitochondria, cells were incubated with 
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (Sigma) with the indicated 
concentrations for the indicated times after GFP-Parkin was transfected into cells for 24 
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h. To induce Parkin translocation with overexpression of VDAC1, FLAG-VDAC1 was 
co-transfected with GFP-Parkin into cells for 12 h. To induce Parkin translocation with 
overexpression of PINK1, PINK1-FLAG was co-transfected with GFP-Parkin into cells 
for 12 h. To rescue Parkin translocation to the mitochondria, 2mM N-Acetyl-L-cysteine 
(NAC) and/or 1,000 U/ml catalase were added as indicated during induction of Parkin 
translocation. 
 
2.3 real-time PCR 
Real-time PCR analysis was carried out using iQ™ SYBR® Green Supermix (Bio-Rad) 
with CFX384TM Real-time PCR Detection System (Bio-Rad). The Real-time PCR 
reaction is shown in Table 2.12. The PCR cycle parameters are shown in Table 2.13. 
The sequences of primers used are shown in Table 2.14. 









Component Volume (μl) 
cDNA (50ng/ul) 1-2 
Forward primer (1 nM) 1 
Reverse primer (1 nM) 1 
iQ™ SYBR® Green Supermix 10 
Double-distilled water Top up to 20 μl 
Total volume 25 




Table 2.13 Real-time PCR cycle parameter 
 
 









Cycle Step Temperature (°C) Time 
1 Initialization 95 3 min 
 
40 
Denaturation 95 10 s 
Annealing and extension 60 30 s 
Insert Primer (5’-3’) 
ACTB Forward-CGGCATCGTCACCAACTG 
Reverse- AACATGATCTGGGTCATCTTCTC 
PINK1 Forward- GGACACGAGACGCTTGCA 
Reverse- CTTACCAATGGACTGCCCTATCA 




Cells were solubilized in a lysis buffer (50 mM Tris-HCl, pH 7.4, 10% glycerol, 1% (v/v) 
Triton X-100, 100 mM NaCl and 0.5 mM MgCl2) supplemented with protease inhibitors, 
including 10 μg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 1 μM pepstatin, and 
leupeptin. The lysates were clarified by centrifugation at 16,000xg for 30 min at 4 °C. 
Protein concentrations of cell lysates were measured using protein assay reagent 
(Bio-Rad) before the samples were denatured at 95°C for 5 min with 6×Laemmli buffer. 
Protein samples were loaded onto and separated in 10% sodium deodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred to polyvinylidene 
difluoride (PVDF) membranes (Millipore). PVDF membranes were blocked with either 
5% skim milk or 5% BSA for 1 h before incubating with primary antibodies at 4°C 
overnight. The primary antibodies used in the study include mouse anti-FLAG (F1804; 
Sigma, 1:30,000 dilution), mouse anti-GAPDH (sc-47724; Santa Cruz Biotechnology, 
1:1,000 dilution) and rabbit anti-PINK1 (BC100-494; Novus, 1:1,000 dilution). The 
PVDF membranes were washed with 1 × TBST buffer and incubated with horseradish 
peroxidase (HRP) conjugated secondary antibodies (Santa Cruz Biotechnology) for 45 
min before it was washed again and detected with West Dura Extender Duration Substrate 
(Thermo Scientific).  
 
2.5 Immunoprecipitation 
To investigate Parkin-mediated ubiquitination of VDAC1 in vivo, GFP-Parkin and 
FLAG, FLAG-VDAC1 or FLAG-6A were cotransfected to 293T cells with 
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HA-ubiquitin K27, K48 or K63 respectively. After 16 hours, cells were treated with 
CCCP for 2 hours then were lysed. Cell lysates were incubated with FLAG M2 beads 
(Sigma-Aldrich) for 3 hours at 4 °C with shaking. After incubation, the beads were 
washed with lysis buffer for 5 times at 4 °C. The immunocomplexes were resolved in 2 
× SDS loading buffer for 10 min at 95 °C and proteins were analyzed by Western 
blotting. Ubiquitination of VDAC1 was detected using HA antibody. VDAC1 and 
Parkin were shown by immunoblotting with anti-FLAG, anti-GFP antibodies.  
 
2.6 Immunofluorescence 
For immunostaining, HeLa cells were seeded on sterilized glass coverslips in 12-well 
plates before fixed with freshly prepared 4% paraformaldehyde in phosphate-buffered 
saline (PBS) for 15 min at room temperature. Cells then were permeabilized and blocked 
with 1x PBS containing 0.5% Triton X-100 and 3% BSA for 30 min at room 
temperature before incubated with the primary antibodies at 4°C overnight. The primary 
antibodies used were mouse anti-Tom20 (sc-17764; Santa Cruz Biotechnology, 1:2,000 
dilution), mouse anti-TRAP1 (ab2721; Abcam, 1:200 dilution) and rabbit anti-FLAG 
(A00170; GenScript, 1:200 dilution). Primary antibodies were washed in the following 
day with 1x PBS before incubated with secondary antibodies for 45 min at room 
temperature. The secondary antibodies used were Alexa Fluor dye-conjugated goat 
anti-mouse, goat anti-rabbit (Invitrogen 1:200 dilution). DNA was stained using 
Hoechst 33342 (Invitrogen) for 10 min at room temperature after secondary antibodies 
were washed with PBS. Cells stained were mounted onto glass slides using 
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FluorSaveTM reagent (Calbiochem). All fluorescent images were acquired on Ultraview 
Vox spinning disc confocal system (PerkinElmer) equipped with a 60× 1.2 N.A. 
objective (Olympus). The brightness of the images was adjusted using Volocity Suite 
(PerkinElmer). 
 
2.7 ROS and mitochondrial potential detection 
To test levels of ROS and mitochondrial potential, fluorescent indicator DHE 
(Invitrogen) and JC-1 (Invitrogen) were used. Cells were harvested, washed in PBS and 
stained with 5 µM DHE or 2 µM JC-1 dye for 30 min at 37 °C in the dark. Fluorescence 
was measured immediately with LSRFortessa (BD Biosciences), and the data were 
analyzed with the FACSDiva version 6.2 software (BD Biosciences). The fluorescence 
intensity of the red signal in DHE stained cells indicates ROS level. The ratio of the red 
to green fluorescence intensity in JC-1 stained cells was used to represent mitochondrial 
membrane potential. To detect ROS and mitochondrial potential in 
BFP-T2A-FLAG-VDAC1 overexpressed cells, DHE or JC-1 signals were measured in 
BFP positive cells.  
 
2.8 Statistical analysis 
The data were presented as the mean + SEM/SD. SEM was calculated as standard 
deviation/√(sample size). Statistical significance was calculated using Student's t-test. 
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Chapter 3 Results 
3.1 ROS regulate PINK1-dependent Parkin translocation to mitochondria 
3.1.1 Test of efficacy of PINK1 shRNAs and validation of PINK1 knockdown HeLa 
cell line 
PINK1 accumulates on the OMM upon mitochondrial depolarization induced by CCCP 
treatment and recruits Parkin exclusively to the damaged mitochondria. Moreover, Parkin 
recruitment to the impaired mitochondria is completely blocked by depletion of PINK1 
(Cai et al., 2012; Matsuda et al., 2010; Narendra et al., 2010b; Vives-Bauza et al., 2010; 
Ziviani et al., 2010). Thus, it has been proposed that the increased protein levels of 
PINK1 caused by CCCP treatment are responsible for the induction of Parkin recruitment. 
To explore the relationship between the protein levels of PINK1 and Parkin recruitment, I 
established a stable PINK1-knockdown HeLa cell line using shRNA-mediated gene 
silencing. Because reduction of PINK1 levels significantly compromises CCCP-induced 
Parkin translocation to mitochondria, the event of Parkin translocation was used as a 
readout for the efficacy of PINK1 knockdown. The results showed that CCCP failed to 
induce Parkin translocation to mitochondria in the presence of PINK1 shRNAs but not 
control luciferase shRNA, indicating that the shRNAs of PINK1 were able to 
significantly decrease the protein levels of PINK1 (Figure 3.1A).  
 
To establish a stable PINK1-knockdown HeLa cell line, the PINK1 shRNAs were 
transfected into HeLa cells. Two days after transfection, 1.0µg/ml puromycin was added 
to select the cells with PINK1 shRNAs integrated into the genome. Only the cells with 
Chapter 3 Results 
73 
 
transfection of PINK1 shRNA #1 grew with resistance to puromycin selection. The cells 
were validated of PINK1 knockdown using real-time PCR and Western blot analysis. The 
mRNA levels of PINK1 in the stable PINK1-knockdown HeLa cell line were reduced to 
less than 10% of that in stable luciferase-knockdown HeLa cell line as a control (Figure 
3.1B). Western blot analysis result showed that PINK1 level was significantly reduced in 
the stable PINK1-knockdown cell line compared with stable control-knockdown cell line. 
Furthermore, both the full-length of PINK1 and the processed form of PINK1 failed to be 
accumulated upon CCCP treatment or MG132 treatment, respectively (Figure 3.1C).  
  















Figure 3.1 PINK1 knockdown in HeLa cells. 
(A) HeLa cells were transfected with GFP-Parkin (green) and luciferase shRNA or 
PINK1 shRNA as indicated. 48 h after transfection, cells were treated with 10 μM CCCP 
for 2 h. Cells were fixed and immunostained for Tom20 (mitochondria, red) and nuclei 
(Hoechst 33258, blue). (B) RNAs in a stable control HeLa cell line and a stable 
PINK1-knockdown cell line were extracted and converted to single-stranded cDNA for 
analyzing by real-time PCR. The relative expression level of PINK1 was assessed by 
normalizing to the housekeeping genes ACTB. (C) Cell lysates from a stable control 
HeLa cell line and a stable PINK1-knockdown cell line treated with DMSO, 10 μM 
MG132 or 10 μM CCCP for 2 h were run on a SDS-PAGE and immunoblotted for PINK1 
or GAPDH. For immunoblotting of PINK1, full-length (FL) PINK1 was robustly 
accumulated upon CCCP treatment in control cells, while 52-kD PINK1 became visible 
upon MG132 treatment also only in control cells. Arrow, FL PINK1; Asterisk, 52-kD 
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3.1.2 An elevated level of PINK1 is not necessary for Parkin translocation to 
mitochondria  
In these stable PINK1-knockdown cells, we transfected GFP-Parkin and treated the cells 
with 10 μM CCCP for different durations (Figure 3.2A). The recruitment of Parkin and 
the levels of PINK1 were assessed by immunofluorescence and Western blot, respectively. 
Consistent with previous studies, Parkin translocation to mitochondria was almost 
completely abolished in the stable PINK1-knockdown HeLa cells after a final 
concentration of 10 μM CCCP treatment for 2 h. However, Parkin recruitment to 
mitochondria in PINK1-knockdown cells was restored to a similar level as that in control 
cells after 8 h of 10 μM CCCP treatment (Figure 3.2B). Western blot analysis showed that 
CCCP treatment induced a moderate accumulation of PINK1 in the PINK1-knockdown 
cells after 10 μM CCCP treatment for 2 h, compared to that of control. However, the 
accumulation of PINK1 ceased with time from 2 h to 8 h. Importantly, the elevated 
protein level of PINK1 in the PINK1-knockdown cells induced by 10 μM CCCP 
treatment for 8 h was significantly lower than that in the control cells without CCCP 
treatment (Figure 3.2C), where Parkin was not recruited to mitochondria. Thereby, our 


























Figure 3.2 Increased level of PINK1 is dispensable for Parkin translocation to 
mitochondria. 
(A) HeLa ells stably expressing PINK1 shRNA were transfected with GFP-Parkin (green) 
and treated with 10 μM CCCP for the indicated times. Cells were fixed and 
immunostained for TRAP1 (mitochondria, red) and nuclei (Hoechst 33258, blue). (B) 
Cells were scored for GFP-Parkin on mitochondria following treatment as described in 
(A). The error bars represent SEM from three independent experiments; at least 100 cells 
were analyzed per experiment. The asterisk denotes statistical significance (p < 0.01); NS, 
not significant (p > 0.05). (C) HeLa cells stably expressing control shRNA or PINK1 
shRNA were treated with 10 μM CCCP for the indicated times. Lysates were harvested 
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3.1.3 An elevated PINK1 level is not sufficient to trigger Parkin recruitment. 
In addition, we investigated the impact of a long-term low dosage CCCP treatment on the 
levels of PINK1 and Parkin recruitment to mitochondria. HeLa cells were treated with 5 
μM CCCP for the indicated times or 10 μM CCCP for 2 h (Figure 3.3A). As shown in 
Figure 3.3B, Parkin was hardly recruited to mitochondria upon CCCP treatment at 5 μM 
for 8 h (Figure 3.3B). However, the levels of PINK1 gradually increased with time upon 
5μM CCCP treatment and the level of PINK1 after 8 h of 5 μM CCCP treatment was 
enhanced to a similar level as that induced by the treatment of 10 μM CCCP for 2 h 
(Figure 3.3C), indicating that an elevated PINK1 level is not sufficient to trigger Parkin 
recruitment. To clarify whether 5 μM CCCP treatment accumulated PINK1 on 
mitochondria, HeLa cells with PINK1-GFP transfection were exposed to 10 μM CCCP 
for 2 h or 5 μM CCCP for 8 h and subject to immunofluorescence analysis. Upon control 
treatment, PINK1-GFP distributed evenly in the cells, forming a few puncta. PINK1-GFP 
showed no significant co-localization with mitochondria marker. As reported in previous 
literature, a treatment of 10 μM CCCP for 2 h was able to induce an accumulation of 
PINK1 on mitochondria. Interestingly, an 8 h treatment of 5 μM CCCP accumulated 
PINK1 on mitochondria. (Figure 3.3D)  
 
  





















Figure 3.3 Mitochondrial accumulated PINK1 is not sufficient for Parkin 
translocation. 
(A) HeLa cells were transfected with GFP-Parkin (green) and treated with 5 μM or 10 μM 
CCCP for the indicated times. Fixed cells were stained for TRAP1 (mitochondria, red) 
and nuclei (Hoechst 33258, blue). (B) Cells were scored for GFP-Parkin on mitochondria 
following treatment as described in (A). (C) HeLa cells were treated with 5 μM or 10 μM 
CCCP for the indicated times. Cell lysates were harvested and run on a SDS-PAGE and 
immunoblotted for PINK1 or GAPDH. (D) HeLa cells were transfected with PINK1-GFP 
(green) and treated with DMSO, 5 μM or 10 μM CCCP for the indicated times. Fixed 
cells were stained for Tim23 (mitochondria, red) and nuclei (Hoechst 33258, blue). (Scale 
bars, 10 µm) 
C 
D 
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3.1.4 Time- and dose-dependent effects of CCCP on mitochondrial potential and 
ROS production 
The phenotypes observed above prompted us to search for other factors involved in the 
CCCP-induced Parkin translocation to mitochondria. To clarify the mitochondrial 
potential and ROS status in cells upon CCCP stress, we examined the mitochondrial 
potential and ROS levels following CCCP treatment in HeLa cells using the fluorescent 
dye JC-1 and dihydroethidium (DHE). As expected, 10 μM CCCP led to mitochondrial 
depolarization in a time-dependent manner, where CCCP started to disrupt the 
mitochondrial potential within 0.5 h and reached its maximum effects at 1 h (Figure 3.4A). 
However, CCCP treatment at different concentrations caused different effects on 
mitochondrial depolarization. A concentration of 2.5 μM CCCP enhanced mitochondrial 
potential, while CCCP treatment at more than 5 μM concentrations depolarized 
mitochondria. Mitochondrial depolarization became more severe with increasing dosages 
of CCCP beyond 5 μM (Figure 3.4B). 
 
  









Figure 3.4 mitochondrial potential in HeLa cells treated with CCCP.  
Mitochondrial potential was measured by flow cytometry of JC-1 fluorescence in HeLa 
cells treated with 10 μM CCCP for the indicated times (A) or treated with CCCP at the 
indicated concentrations for 2 h (B). The error bars represent SEM from three 
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It is understandable that CCCP causes an uncoupling of the proton gradient, disrupting 
mitochondrial potential in a time- and dose-dependent manner. However, the role of 
CCCP in the production of ROS has not been well studied. It was found that a supplement 
of CCCP led to decreased ROS production, probably due to accelerated passage of 
electrons down the transport chain and elimination of electron-rich intermediates by 
CCCP (Li et al., 2004). However, the concentration of CCCP applied was 1 μM, which 
was much lower than the concentration currently used to depolarize mitochondria and 
induce Parkin translocation to mitochondria (Narendra et al., 2008). Therefore, we 
examined the effects of CCCP on ROS production. 10 μM CCCP led to a gradual increase 
of ROS levels with time as indicated by DHE staining. Within 0.5 h of CCCP treatment, 
CCCP triggered the generation of ROS (Figure 3.5A). In terms of the relationship 
between the dosage of CCCP and ROS levels, a treatment of 2.5 μM CCCP slightly 
decreased ROS production, while CCCP treatment at more than 5 μM boosted ROS 











Figure 3.5 ROS production in HeLa cells treated with CCCP.  
ROS were measured by flow cytometry of DHE fluorescence in HeLa cells treated with 
10 μM CCCP for the indicated times (A) or treated with CCCP at the indicated 
concentrations for 2 h (B). 
  
B 
Chapter 3 Results 
86 
 
3.1.5 Insignificant effects of ROS scavengers on Parkin recruitment 
As mentioned earlier, the role of ROS in mitophagy is yet to be determined because the 
results were mixed when it comes to different mitophagy inducers and cell types. 
However, it is consistent that ROS scavengers failed to reverse Parkin recruitment 
induced by CCCP in HeLa cells. Given our findings that CCCP led to ROS burst in cells, 
the next question we asked was whether ROS scavengers could inhibit Parkin recruitment 
and whether ROS scavengers could efficiently quench ROS generated by CCCP. 
Consistent with previous studies, neither N-Acetyl-L-cysteine (NAC) nor catalase was 
able to suppress the translocation of Parkin to mitochondria (Figure 3.6A, B). The failure 
has been used as an evidence to show that ROS play an insignificant role in Parkin 









Figure 3.6 NAC or catalase treatment fails to inhibit Parkin recruitment to 
mitochondria. 
 (A) HeLa cells were transfected with GFP-Parkin (green) and treated with 10 μM CCCP 
for 2 h in the presence or absence of 1,000 U/ml catalase or 2mM NAC. Fixed cells were 
stained for Tom20 (mitochondria, red) and nuclei (Hoechst 33258, blue). (B) Cells were 
scored for GFP-Parkin on mitochondria following treatment as described in (A). The 
error bars represent SEM from three independent experiments; at least 100 cells were 
analyzed per experiment. NS, not significant (p > 0.05) (Scale bars, 10 µm) 
  
B 
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3.1.6 The production of ROS in HeLa cells with the treatment of both CCCP and 
ROS scavenger 
We were interested in the efficacy of ROS scavengers applied in the studies. To this end, 
we examined ROS status in HeLa cells with the presence of both CCCP and ROS 
scavengers. Our results showed that a concentration of 1,000 U/ml catalase was able to 
quench ROS induced by 10 μM CCCP at 0.5 h. Nevertheless, the levels of ROS gradually 
increased after 10 μM CCCP treatment for 0.5 h, despite the presence of 1,000 U/ml 
catalase (Figure 3.7A). In contrast, a treatment of 2 mM NAC could not effectively 
suppress the effect of 10 μM CCCP-induced ROS production within 0.5 h, although it 
effectively eliminated ROS production after 1 h (Figure 3.7B). These data indicate that 
the failure of ROS scavengers to rescue CCCP-induced Parkin translocation to 











Figure 3.7 Effects of ROS scavengers on ROS production induced by CCCP. 
HeLa cells were treated with 10 μM CCCP and 1,000 U/ml catalase (A) or 2mM NAC (B) 
for the indicated times. The cells were harvested and stained with DHE, followed by flow 
cytometric analysis. The error bars represent SEM from three independent experiments; 
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3.1.7 NAC significantly reduces the recruitment of Parkin to mitochondria induced 
by 7.5 μM CCCP 
Based on our understanding that ROS scavengers could not completely suppress the 
production of CCCP-induced ROS, we next tried to manipulate the drugs involved to 
investigate the role of ROS in the recruitment of Parkin. As shown in Figure 3.6B, the 
treatment of 2mM NAC failed to rescue 10μM CCCP-induced Parkin translocation to 
mitochondria. Similarly, 2mM NAC could not quench ROS induced by 10 μM CCCP at 
0.5h either (Figure 3.7B). In addition, a concentration of 7.5 μM CCCP triggered much 
less ROS production than that of 10 μM CCCP treatment (Figure 3.5B). Therefore, we 
examined Parkin recruitment induced by 7.5 μM CCCP and how 2mM NAC affected the 
recruitment of Parkin and the level of ROS induced by 7.5 μM CCCP. We found that 7.5 
μM CCCP induced dramatic Parkin translocation to mitochondria in approximately 90% 
of the cells (Figure 3.8A). Intriguingly, 2 mM NAC significantly attenuated the 
redistribution of Parkin to mitochondria induced by 7.5 μM CCCP. The overlapping of 















Figure 3.8 7.5 μM CCCP-induced Parkin recruitment was reversed by 2mM NAC.  
(A) HeLa cells were transfected with GFP-Parkin (green) and treated with 7.5 μM CCCP 
in the presence or absence of 2mM NAC for 2 h. Cells were fixed and stained for Tom20 
(mitochondria, red) and nuclei (Hoechst 33258, blue). (B) Cells were scored for 
GFP-Parkin on mitochondria following treatment as described in (A). The error bars 
represent SEM from three independent experiments; at least 100 cells were analyzed per 
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Since NAC failed to ablate ROS outburst induced by 10 μM CCCP only at 0.5 h, we 
checked the ROS level at 0.5 h after adding 7.5 μM CCCP and 2 mM NAC. As expected, 
2mM NAC was able to reduce ROS production induced by 7.5 μM CCCP to a similar 
level as control (Figure 3.8A). Moreover, depolarization of mitochondria was not 




Figure 3.9 Effects of 7.5 μM CCCP and 2mM NAC on ROS production and 
mitochondrial potential.  
HeLa cells were treated with or without 2mM NAC, 7.5 μM CCCP or in combination as 
indicated for 0.5 h. Cells were harvested and stained with DHE (A) or JC-1 (B) followed 
by flow cytometric analysis. The error bars represent SEM from three independent 
experiments; at least 10,000 cells were analyzed per experiment. The asterisk denotes 
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3.1.8 CCCP-induced Parkin recruitment is blocked by the combinatorial treatment 
of NAC and catalase 
We noticed that catalase efficiently quenched ROS production in the first 0.5 h (Figure 
3.7A), while NAC was only able to inhibit ROS generation after 0.5 h (Figure 3.7B). 
Therefore, we were interested in testing the effects of the combination of NAC and 
catalase on Parkin recruitment. Furthermore, could the combination of these two ROS 
scavengers further enhance their ability to overcome the outburst of ROS in response to 
CCCP treatment? Indeed, we found that the combinatorial treatment of 2 mM NAC and 
1,000 U/ml catalase almost completely abolished Parkin accumulation on mitochondria 










Figure 3.10 CCCP-induced Parkin recruitment is abolished by the combinatorial 
treatment of NAC and catalase. 
(A) HeLa cells were transfected with GFP-Parkin (green) and treated with 10 μM CCCP 
for 2 h in the presence or absence of 2 mM NAC and 1,000 U/ml catalase. Fixed cells 
were stained for Tom20 (mitochondria, red) and nuclei (Hoechst 33258, blue). (B) Cells 
were scored for GFP-Parkin on mitochondria following treatment as described in (A). 
The asterisk denotes statistical significance (p < 0.01). (Scale bars, 10 µm) 
  
B 
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2 mM NAC and 1,000 U/ml catalase were also found to completely quench ROS 
production induced by 10 μM CCCP (Figure 3.11A). However, the combinatorial 
treatment of NAC and catalase also significantly attenuated mitochondrial depolarization 
in response to CCCP treatment (Figure 3.11B). Taken together, our data suggest that ROS 
may be important for Parkin recruitment to mitochondria, as ROS scavengers are able to 




Figure 3.11 Effects of 10 μM CCCP and combinatory treatment of NAC and 
catalase on ROS production and mitochondrial potential. 
HeLa cells were treated with or without CCCP, NAC and catalase as indicated for 0.5 h. 
The cells were harvested and stained with DHE (A) or JC-1 (B) followed by flow 
A 
B 
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cytometric analysis. The asterisk denotes statistical significance (p < 0.05); NS, not 
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3.1.9 VDAC1 overexpression-induced Parkin recruitment to mitochondria 
Because ROS scavengers may affect both mitochondrial depolarization and ROS 
production in response to CCCP treatment, we sought to use a different approach to 
stimulate ROS production alone, which triggers Parkin translocation without affecting 
mitochondrial potential. However, ROS outburst and mitochondrial depolarization are 
usually intertwined. For instance, chemicals such as CCCP and paraquat usually 
depolarize mitochondria and trigger ROS generation concurrently (Narendra et al., 2008). 
A photosensitizer, KillerRed, which stimulates ROS production upon photoactivation and 
triggers Parkin-mediated mitophagy, disrupts mitochondrial potential (Wang et al., 2012). 
Hence, we were motivated to employ a genetic approach to separate these two events. 
VDAC1 mediates the release of ROS from mitochondrial matrix to cytoplasm and 
overexpression of VDAC1 increases the levels of ROS (Shoshan-Barmatz et al., 2010). 
Moreover, VDAC1 has recently been identified as a substrate on mitochondria for Parkin 
after CCCP treatment (Sun et al., 2012). In this study, we examined the effect of 
overexpression of VDAC1 on Parkin recruitment to mitochondria. As shown in Figure 
3.12A and B, Parkin was recruited to mitochondria in approximately 30% of 
VDAC1-overexpressing cells.  
 
A 





Figure 3.12 VDAC1 overexpression-induced Parkin recruitment to mitochondria. 
(A) HeLa cells were transfected with GFP-Parkin (green) and FLAG or FLAG-VDAC1. 
After 12 h, cells were fixed and immunostained for TRAP1 (mitochondria, red), FLAG 
(purple) and nuclei (Hoechst 33258, blue). (B) Cells were scored for GFP-Parkin on 
mitochondria in HeLa cells transiently overexpressing FLAG or FLAG-VDAC1. The 
error bars represent SEM from three independent experiments; at least 100 cells were 
analyzed per experiment. The asterisk denotes statistical significance (p < 0.01). (Scale 
bars, 10 µm) 
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3.1.10 VDAC1 overexpression-induced Parkin recruitment is PINK1-dependent 
To clarify if the VDAC1-induced Parkin recruitment is PINK1 related, we co-transfected 
VDAC1 and Parkin into stable PINK1-knockdown HeLa cells and found that Parkin 
recruitment was significantly reduced, as Parkin colocalized with mitochondria in less 
than 5% of the cells (Figure 3.13A, B). Intriguingly, the levels of PINK1 in 
VDAC1-overexpresing cells did not increase compared to that in control cells (Figure 
3.13C). This result further corroborates our hypothesis that an elevated level of PINK1 is 














Figure 3.13 VDAC1 overexpression-induced Parkin recruitment is PINK1- 
dependent. 
(A) GFP-Parkin and FLAG-VDAC1 were transfected into HeLa cells stably expressing 
control-shRNA or PINK1-shRNA. 12 h after transfection, cells were fixed and 
immunostained for TRAP1 (mitochondria, red), FLAG (purple) and nuclei (Hoechst 
33258, blue). (B) Cells were scored for the presence of GFP-Parkin on mitochondria. The 
asterisk denotes statistical significance (p < 0.01). (C) HeLa cells were transfected with 
FLAG or FLAG-VDAC1. 12 h after transfection, cells were harvested and analyzed by 
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3.1.11 Phosphorylation of Parkin at Ser65 may play an important role in Parkin 
recruitment 
A few features of PINK1-dependent Parkin translocation to mitochondrial have been 
characterized, including the necessity of PINK1 kinase activity and phosphorylation of 
Parkin at Ser65 (Kondapalli et al., 2012). To further confirm that overexpression of 
VDAC1-induced Parkin recruitment is achieved through the same pathway as 
CCCP-induced Parkin recruitment, we examined the role of phosphorylation of Parkin at 
Ser65 in Parkin recruitment in response to overexpression of VDAC1, using 
phospho-deficient and phospho-mimetic mutants of Parkin. As shown in Figure 3.13A, 
similar to wild-type Parkin, the S65A and S65E mutants of Parkin evenly distributed 
throughout an entire cell. As shown in Figure3.13B, upon CCCP treatment, the S65A 
mutant of Parkin translocation to mitochondrial was significantly impeded. This result is 
consistent with that in the previous literature (Kondapalli et al., 2012). For VDAC1 
overexpression-induced Parkin recruitment to mitochondria, the S65A mutation of Parkin 
also dramatically suppressed Parkin recruitment (Figure 3.13C, D).  
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Figure 3.14 The Ser65 residue of Parkin is crucial for VDAC1 
overexpression-induced Parkin recruitment.  
Wild type Parkin, S65A or S65E mutant of Parkin was transfected into HeLa cells. 24 h 
after transfection, cells were treated with DMSO (A) or CCCP (B) for 2 h before they 
were fixed and immunostained for Tom20 (mitochondria, green), FLAG (red) and nuclei 
(Hoechst 33258, blue). (C) Wild type Parkin, S65A or S65E mutant of Parkin was 
transfected into HeLa cells along with Myc-VDAC1. 12 h after transfection, cells were 
fixed and immunostained for Myc (green), FLAG (red) and nuclei (Hoechst 33258, blue). 
Cells were scored for GFP-Parkin on mitochondria in VDAC1 overexpressed HeLa cells. 
The error bars represent SEM from three independent experiments; at least 100 cells were 
analyzed per experiment. 
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3.1.12 Construction of a BFP-T2A-FLAG-VDAC1 plasmid for flow cytometric 
analysis 
To test if ROS play a fundamental role in Parkin translocation in response to 
overexpression of VDAC1, we first checked whether the levels of ROS were changed by 
overexpression of VDAC1 in cells. VDAC1 plasmids with a fluorescent tag at its either N 
or C terminus were constructed for flow cytometric analysis. However, both N terminus 
and C terminus GFP-tagged VDAC1 expressed evenly or in a puncta-like pattern in the 
cells (Figure 3.15A), suggesting that the GFP tag compromises the proper localization of 
VDAC1 to the OMM. To express VDAC1 with a fluorescent tag in cells without affecting 
VDAC1 localization, we designed a BFP-T2A-FLAG-VDAC1 plasmid construct which 
consists of a T2A sequence between the BFP and FLAG tags. The T2A sequence is 
skipped by the ribosome during translation, leading to “self-cleavage” and separation of 
its adjacent proteins (Kim et al., 2011). Once expressed in the cells, the BFP tag will be 
used as a reporter to indicate the presence of ectopic VDAC1, while the FLAG tag can be 
immunostained to show the expression pattern of VDAC1. Immunostaining data showed 
that BFP signals ubiquitously distributed in the cell, while FLAG signals showed perfect 
collocaliztion with the mitochondrial marker Tom20 (Figure 3.15B), indicating 











Figure 3.15 Localization of VDAC1 with different tags. 
(A) HeLa cells were transfected with GFP-VDAC1 (green) or VDAC1-GFP (green). 
After 16 h, cells were fixed and immunostained for Tom20 (mitochondria, red) and nuclei 
(Hoechst 33258, blue). (B) HeLa cells were transfected with FLAG-VDAC1 or 
BFP-T2A-FLAG-VDAC1 (blue). After 16 h, cells were fixed and immunostained for 
Tom20 (mitochondria, green) and FLAG (red). (Scale bars, 10 µm) 
B 
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3.1.13 Inhibition of Parkin translocation to mitochondria by ROS scavengers 
We examined ROS production and mitochondrial potential in HeLa cells overexpressing 
BFP-T2A-FLAG-VDAC1 by flow cytometric analysis. As shown in Figure3.16A and B, 
overexpression of VDAC1 significantly increased ROS production by approximately 30% 
(Figure 3.16A), but had no effect on mitochondrial potential (Figure 3.16B). Next, we 
asked if ROS scavengers were able to rescue VDAC1-induced Parkin translocation to 
mitochondria. Similar to the rescue in CCCP-induced Parkin translocation to 
mitochondria by ROS scavengers, the combinatorial treatment of 2 mM NAC and 1,000 
U/ml catalase dramatically attenuated VDAC1-induced Parkin accumulation to 
mitochondria, while 2 mM NAC or 1,000 U/ml catalase alone had little effect on VDAC1 





















Figure 3.16 Inhibition of Parkin translocation to mitochondria by ROS scavengers. 
HeLa cells were transfected with BFP or BFP-T2A-FLAG-VDAC1. 12 h after 
transfection, cells were harvested and stained with DHE (A) or JC-1 (B) and followed by 
flow cytometric analysis. DHE or JC-1 fluorescence was measured in BFP positive cells. 
The error bars represent SEM from three independent experiments; at least 10,000 BFP 
positive cells were analyzed per experiment. The asterisk denotes statistical significance 
(p < 0.05); NS, not significant (p > 0.05). (C) HeLa cells were transfected with 
GFP-Parkin (green) and FLAG-VDAC1. Cells were simultaneously treated with or 
without 2mM NAC, 1,000 U/ml catalase or in combination. The medium was removed 
and replenished with fresh medium with or without NAC and catalase at 4 h, 7 h and 10 h 
after transfection. After 12 h, cells were fixed and immunostained for Tom20 
(mitochondria, red) and FLAG (purple). (D) Cells were scored for GFP-Parkin on 
mitochondria following treatment as described in (C). The error bars represent SEM from 
three independent experiments; at least 100 cells were analyzed per experiment. The 
asterisk denotes statistical significance (p < 0.01); NS, not significant (p > 0.05). 
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3.1.14 ROS scavengers suppress Parkin translocation to mitochondria by 
quenching ROS production induced by VDAC1 overexpression  
Consistently, the combinatorial treatment of NAC and catalase but not NAC or catalase 
treatment alone was adequate to quench the ROS generation induced by VDAC1 
overexpression (Figure 3.17A). In addition, the combinatory treatment of NAC and 
catalase did not affect the protein expression levels of VDAC1 or Parkin (Figure 3.17B). 
This ruled out the possibility that ROS scavengers rescued VDAC1-induced Parkin 











Figure 3.17 ROS scavengers extinguish ROS production induced by VDAC1 
overexpression. 
(A) HeLa cells were transfected with BFP or BFP-T2A-FLAG-VDAC1 and were 
simultaneously treated with or without 1,000 U/ml catalase, 2mM NAC or in 
combination as indicated. The medium was removed and replenished with fresh medium 
with or without NAC and catalase at 4 h, 7 h and 10 h after transfection. After 12 h, cells 
were harvested and stained with DHE and followed by flow cytometric analysis. DHE 
fluorescence was measured in BFP positive cells. The asterisk denotes statistical 
significance (p < 0.01); NS, not significant (p > 0.05). (B) HeLa cells were transfected 
with GFP-Parkin (green) and FLAG-VDAC1. Cells were simultaneously treated with or 
without 2mM NAC and 1,000 U/ml catalase. The medium was changed as in (A). After 
12 h, cells were harvested and protein extracts were assayed for the levels of GFP-Parkin 
and FLAG-VDAC1 by immunoblotting. (Scale bars, 10 µm) 
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3.2 The role of phosphorylation-dependent ubiquitination of VDAC1 in mitophagy 
3.2.1 Phosphorylation of VDAC1 may be important for its ubiquitination 
It has been found that VDAC1 acts as an adaptor protein on mitochondria for Parkin 
translocation (Sun et al., 2012). In addition, VDAC1, an OMM protein, has been 
demonstrated to be heavily ubiquitinated by Parkin during mitophagy, may serve as the 
“bait”, alluring Parkin to translocate to mitochondria (Geisler et al., 2010). We therefore 
reasoned if phosphorylation of VDAC1 on certain motifs is necessary for ubiquitination, 
inhibition of phosphorylation should prevent the ubiquitination of VDAC1. To verify the 
postulation, we mutated the majority of the serine/threonine (S/T) sites to alanine (A) in 
VDAC1. The selected S/T sites for this study mainly localize on or near the loop regions 
of VDAC1. For other S/T sites in the β strands, they are either immersed in the 
hydrophobic lipid bilayer of the OMM or face to the pore of the barrel of VDAC1. These 
S/T sites are hardly accessed by kinases. To intensively screen the function of the S/T 
residues, some of the mutants harbor single mutation of S/T to A, the others containing 
two or three adjacent S/T to A mutations. To test if ubiquitination of VDAC1 is affected 
by its phosphorylation, the extent of ubiquitination of each VDAC1 mutants was 
examined by Western blot analysis. Previous literature showed that the ubiquitination of 
VDAC1 could be clearly seen in the whole cell lysate (Geisler et al., 2010). Therefore, we 
adopted the same method to rapidly screen the effect of the mutation on ubiquitination. 
As shown in Figure 3.18A and B, among all the mutants tested, the ubiquitination was 
markedly reduced in six mutants (Figure 3.18A, B). Moreover, the combination of these 
six mutations further suppressed the ubiquitination of VDAC1 (Figure 3.18B).  









Figure 3.18 Mutations of serine/threonine in VDAC1 affect its ubiquitination 
during mitophagy. 
(A) The wild type and mutants of FLAG-VDAC1 were transfected into 293T cells along 
with or without GFP-Parkin. After 18 h, the cells were treated with CCCP for 2 h and 
subjected to Western blotting. Yellow boxes highlight VDAC1 mutants with affected 
ubiquitination. (B) The mutants of VDAC1 with single mutation which affects 
ubiquitination and VDAC1 with the combination of S13, S101, S102, T165, S167 and 
T175 to A mutations (6A mutant) were transfected into 293T cells together with or 
without GFP-Parkin. After treated as in (A), cells were subjected to Western blotting.  
B 
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Preliminary screening results provided us an important clue of which S/T sites in VDAC1 
might be pivotal for its ubiquitination, particularly its mono-ubiquitination. To confirm 
the changes in ubiquitination and dissect which ubiquitin branch is most critical for the 
ubiquitination of VDAC1, we conducted in vivo ubiquitination assay. Western blotting 
showed that mutations in VDAC1 are capable to decrease ubiquitination (Figure 3.19A). 
Furthermore, ubiquitination of VDAC1 were mainly mediated by K27 (Figure 3.19B), 























Figure 3.19 Ubiquitination of VDAC1 is affected by its mutation. 
(A) His-ubiquitin and GFP-Parkin were co-transfected to HEK 293T cells with vector 
alone, Myc-VDAC1 or the mutant of Myc-VDAC1 with the combination of S13, S101, 
S102, T165, S167 and T175 to A mutation (Myc-6A). 16 h after transfection, cells were 
treated with CCCP for 2 hours. Lysates were immunoprecipitated with Ni-NTA agarose 
beads (Qiagen) followed by immunoblotting with anti-Myc and anti-GFP antibodies. 
GFP-Parkin and FLAG, FLAG -VDAC1 or FLAG -6A were cotransfected to 293T cells 
with HA-ubiquitin K27 (B), K48 (C) or K63 (D) respectively. After 16 h, cells were 
treated with CCCP for 2 h then were lysed. Ubiquitination of VDAC1 was detected by 
immunoprecipitation with M2-FLAG beads (Sigma) followed by immunoblotting using 
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Although the mutations on S/T residues do affect the ubiquitination of VDAC1, it could 
be due to the structural change induced by the mutations rather than the inhibition of 
phosphorylation. To confirm the S/T sites that we mutated could be phosphorylated in 
vivo, we applied a proteomic study to examine if VDAC1 is phosphorylated after 
depolarization. The mass spectrometry results showed that the residues S101, S102, S167 









Figure 3.20 Phosphorylation of VDAC1 is validated by mass spectrometry. 
The full-length FLAG-VDAC1 was overexpressed in HEK 293T cells. After 18 h, cells 
were treated with CCCP for 2 h and proteins were extracted and incubated with 
FLAG-M2 beads and followed by gel electrophoresis. The resulted band with the 
molecular weight of VDAC1 was excised and analyzed by mass spectrometry.  
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3.2.2 ubiquitination of VDAC1 has no role in mitophagy 
It has been shown that loss of VDAC1 has no effect on Parkin-mediated mitophagy. 
However, this might be due to the presence of other alternative substrates of Parkin, 
which could also be ubiquitinated and trigger subsequent mitophagy. Therefore, it is still 
possible that VDAC1 actually plays a role in mitophagy. To answer the question if the 
ubiquitination of VDAC1 has a role in mitophagy, wild type and mutant VDAC1 were 
introduced into cells to examine if there is any different effect on mitophagy. To eliminate 
the influence of ubiquitination of endogenous VDAC1, stable VDAC1-knockdown HeLa 
cell lines were established. The efficiency of VDAC1 knockdown was validated using 
Western blot analysis (Figure 3.21A). Immunofluorescence data showed that there was 
no significant difference in Parkin translocation among cells transfected with a vector 
















Figure 3.21 Ubiquitination-deficient VDAC1 mutations have no effect on execution 
of mitophagy.  
(A) Cell lysates from a stable control-knockdown HeLa cell line and a stable 
VDAC1-knockdown cell line were run on a SDS-PAGE and immunoblotted for VDAC1 
and β-Tubulin. (B) Stable VDAC1-knockdown HeLa cells were transfect with 
GFP-Parkin and shRNA-resistant wild type or mutant FLAG-VDAC1. After 16 hours, 
cells were treated with CCCP for 24 h and subject to immunofluresence microscopy with 
staining of TRAP1 as a marker for the inner mitochondrial membrane. (C) Cells were 
scored for cleared mitochondria in stable VDAC1-knockdown HeLa cells. The error bars 
represent SEM from three independent experiments; at least 100 cells were analyzed per 
experiment.
C Cleared mitochondria Clustered mitochondria 
B 
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Chapter 4 Discussion 
4.1 The role of PINK1 and Parkin in mitophagy 
Our data showed that accumulation of PINK1 was neither necessary nor sufficient for 
Parkin translocation to mitochondria (Figure 3.2 and 3.3). In contrast, decreased levels of 
PINK1 only delayed the redistribution of Parkin to impaired mitochondria. Moreover, in 
the case of PINK1-dependent Parkin translocation to mitochondria induced by VDAC1 
overexpression, the level of PINK1 was not altered during the process, which further 
supports the idea that the level of PINK1 is not a determining factor in Parkin recruitment 
to mitochondria. However, the presence of PINK1 is still necessary for Parkin 
recruitment, as accumulation of Parkin to depolarized mitochondria was completely 
abolished in PINK1-knockout MEFs even with long-term CCCP exposure (Matsuda et al., 
2010). We also found that VDAC1-induced Parkin translocation to mitochondria was 
significantly reduced by knocking down PINK1. This result supports the pivotal role of 
PINK1 in Parkin recruitment to mitochondria. Taken together, our results indicate that the 
presence of PINK1, instead of its accumulation is essential for Parkin translocation to 
mitochondria. Furthermore, our findings also corroborate the intriguing discovery that 
siRNA-induced loss of PINK1 surprisingly had no effect on CCCP-induced mitophagy 
revealed by fluorescent-tagged mitochondria (Allen et al., 2013). In addition, a 
paradoxical observation showed that PINK1 knockdown promoted ROS-involved 
mitophagy (Dagda et al., 2009). However, our results suggest that PINK1 knockdown 
may significantly increase excessive accumulation of ROS, which activates the 
remaining PINK1 protein, thereby triggering PINK1-dependent mitophagy. Furthermore, 
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since PINK1 knockdown only delays Parkin translocation to mitochondria but does not 
affect PINK1-dependent mitophagy, the study of the role of PINK1 in mitophagy or even 
in other biological processes should be carried out with caution if PINK1 siRNA or 
shRNA is utilized in the research.  
 
An interesting question about the role of Parkin and PINK1 in mitophagy is to what 
extent these two molecules are involved in mitophagy. It has been known that upon 
mitochondrial depolarization, PINK1 accumulates on the OMM and recruits Parkin, 
thereby triggering mitophagy (Geisler et al., 2010; Matsuda et al., 2010). However, have 
Parkin and PINK1 fulfilled their functions once Parkin translocates to mitochondria and 
mediates ubiquitination of proteins on the membrane? The most likely answer is no. It has 
been found that Parkin interacts with an autophagy-promoting protein Ambra1. The 
interaction of Parkin and Ambra1 is significantly promoted by mitochondrial 
depolarization, though no evidence of ubiquitination of Ambra1 by Parkin was found. 
Importantly, Ambra1 is not necessary for Parkin translocation to mitochondria but is 
indispensable for the subsequent mitochondrial removal. This study suggests that Parkin 
is involved in mitophagy through functions beyond its E3 ligase activity (Van Humbeeck 
et al., 2011). On the other hand, the results for the role of PINK1 in autophagy are 
inconsistent. As mentioned earlier, the reduction in protein levels of PINK1 promoted 
ROS-involved mitophagy. However, PINK1 knockdown resulted in a down-regulation of 
key autophagic genes and increased apoptosis (Parganlija et al., 2014). Therefore, it 
would be interesting to examine if PINK1 functions to activate particular autophagic 
Chapter 4 Discussion 
123 
 
machinery during mitophagy. In addition, it is noteworthy that although depletion of 
PINK1 blocks Parkin translocation to mitochondria and probably suppresses subsequent 
mitophagy, reduction of PINK1 only delays Parkin translocation and may have no effect 
on mitophagy. Moreover, it has been demonstrated that most of the mutations on Parkin 
compromises mitophagy in different stages (Lee et al., 2010; Narendra et al., 2010b). 
However, it is not the case for PINK1. At least half of the PD-related PINK1 mutations 
have no impact on Parkin translocation or execution of mitophagy (Matsuda et al., 2010; 
Narendra et al., 2010b). Therefore, the exact roles of Parkin and PINK1 in mitophagy 
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4.2 The role of ROS in mitophagy 
ROS has long been suspected to be involved in PINK1-dependent Parkin redistribution to 
mitochondria (Narendra et al., 2008). After examining the ROS status under the treatment 
of CCCP and ROS scavengers, we reasoned that the inability of ROS scavengers to block 
CCCP-induced Parkin accumulation onto mitochondria is probably due to the inadequacy 
of ROS scavengers on ROS production induced by CCCP treatment in HeLa cells. By 
decreasing CCCP dosages or combining ROS scavengers, we successfully inhibited the 
mitochondrial translocation of Parkin using ROS scavengers, namely catalase and NAC. 
Moreover, we increased levels of ROS in cells by overexpressing VDAC1 and found that 
ROS outburst rather than mitochondrial depolarization were responsible for Parkin 
recruitment to mitochondria induced by VDAC1 overexpression (Figure 3.16). Taken 
together, our study demonstrates that cells may sense ROS produced in damaged 
mitochondria and adopt autophagy to remove the impaired mitochondria. Thus, our 
findings underline the importance of fine-tuning ROS levels in designing PD therapeutic 
strategy. More specifically, suppressing ROS might be beneficial for combating the 
assaults of ROS to cells. But when cells rely on ROS as a signal to initiate autophagy to 
eliminate the dysfunctional mitochondria, quenching ROS in cells without mutations in 
Parkin or PINK1 may bring about devastating consequences as it disturbs the 
homeostasis of cells by blocking the initiation of mitophagy. This may also partially 
explain why no antioxidant has been discovered so far to clinically benefit PD.  
 
Our data elucidate that the accumulation of PINK1 may only accelerate Parkin 
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recruitment to mitochondria rather than play an indispensable role in controlling this 
event. Furthermore, we establish that ROS are an important factor in Parkin translocation 
to mitochondria. Therefore, we propose that excessive ROS, produced by the 
dysfunctional mitochondria, may activate PINK1 thereby triggering Parkin recruitment to 
mitochondria. Because ROS are generated in damaged mitochondria, they may modify 
PINK1 on the impaired mitochondria exclusively. This specific modification ensures the 
specificity of Parkin recruitment to the unhealthy mitochondria. However, we cannot rule 
out the possibility that ROS may modify the other OMM proteins which can be 
phosphorylated by PINK1 and later recognized and docked by Parkin. Another possible 
scenario is that ROS may cause mutations on mtDNA in the affected mitochondria 
(Beckman and Ames, 1998), triggering Parkin translocation to mitochondria and 
inducing mitophagy later on (Suen et al., 2010).  
 
The discovery of the role of ROS in mitophagy initiation also contributes to the 
identification of the bona fide substrates on mitochondria for Parkin recruitment. 
Intensive efforts have been made to clarify the mechanism by which Parkin/PINK1- 
mediated mitophagy is regulated, leading to the discoveries of a few potential targets, 
including: MFN2 (Chen and Dorn, 2013), VDACs(Sun et al., 2012), hexokinase 
(McCoy et al., 2014), and HSPA1L (Hasson et al., 2013). The depletion of any these 
above mitochondrial proteins compromises Parkin recruitment to mitochondria, 
indicating that these molecules may provide the mitochondrial docking sites for Parkin. 
Mitochondrial potential (McCoy et al., 2014; Sun et al., 2012) or the level of PINK1 
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(Hasson et al., 2013) was examined in most of the studies mentioned above, as 
mitochondrial depolarization-induced PINK1 accumulation has been canonically 
considered to be crucial for Parkin redistribution to mitochondria (Narendra et al., 2008). 
Similarly, since we disclosed that ROS also play an essential role in Parkin translocation, 
ROS status should be clarified to ensure that the potential scaffold protein actually 
anchors Parkin to mitochondria rather than the protein affects Parkin translocation 
through its effects on the level of ROS.  
 
There are questions for the role of ROS in mitophagy to be discussed. The first one would 
be which type of ROS plays a more important role for mitophagy. In our study, ROS 
production induced by CCCP and VDAC1 overexpression was detected by DHE, which 
has been used to indicate the superoxide level. However, catalase, which converts 
superoxide to H2O2, only effectively quenches the ROS production in response to CCCP 
treatment in half an hour. Moreover, the combinatorial treatment of NAC and catalase, 
but not NAC alone, is able to extinguish ROS production and suppress Parkin recruitment 
to mitochondria in response to either CCCP treatment or VDAC1 overexpression of 
VDAC1. These data suggest that both superoxide and H2O2 play a pivotal role in Parkin 
translocation. Another question concerning the role of ROS in mitophagy is whether ROS 
are implicated in other stages of mitophagy apart from Parkin translocation to 
mitochondria. In our study, we detected ROS burst in both scenarios of CCCP treatment 
and VDAC1 overexpression. In addition, it is well known that ROS regulate autophagy 
(Scherz-Shouval et al., 2007). Therefore, it is possible that after Parkin ubiquitinates 
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substrate proteins on the OMM, ROS take over to drive mitophagy forward. If so, how do 
ROS facilitate the execution of mitophagy? As it was found that ROS activate autophagy 
by modifying ATG4 (Scherz-Shouval et al., 2007), it is possible that ROS promote 
mitophagy through the same.  
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4.3 The role of VDAC1 in mitophagy 
Though ubiquitin has been shown to be phosphorylated by PINK1 to activate Parkin, the 
driving force to recruit Parkin to mitochondria is still unknown. In another word, 
activation of Parkin by phosphorylated ubiquitin may be crucial for Parkin translocation 
(Kane et al., 2014; Koyano et al., 2014), but it is other molecular events rather than 
phosphorylation of ubiquitin that directly recruit Parkin to mitochondria. Intensive efforts 
have been made to identify common substrates of Parkin and PINK1 in attempt to explain 
how PINK1 recruits Parkin to mitochondria. To find out the substrate for Parkin/PINK1 
on mitochondria, we tested if phosphorylation of VDAC1 had a role in mitophagy. The 
serine and threonine sites on VDAC1 away from the hydrophobic lipid bilayer of the 
OMM were mutated to alanine to check if the ubiquitination and mitophagy were 
compromised. Interestingly, a total of six serine or threonine sites were found to be 
crucial for the ubiquitination of VDAC1 by Parkin. However, mitophagy was not affected 
by the mutations in these sites. There could be a few explanations about this phenotype. 
Firstly, the serine or threonine sites responsible for ubiquitination of VDAC1 may not 
necessarily be important for the docking of Parkin to VDAC1. Therefore, it would be 
interesting to test if the mutations on the serine or threonine site of VDAC1 affect Parkin 
recruitment to mitochondria. Secondly, there might be redundant substrates of Parkin for 
its translocation, while VDAC1 might be the exclusive substrate for Parkin only in certain 
type of cells. A recent study supports the last possibility showing that 
PINK1-phosphorylated MFN2 can be recognized by Parkin and is indispensable for 
Parkin recruitment in mouse cardiomyocyte (Chen and Dorn, 2013). However, double 
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knockout of MFN1/2 even prompts automatic Parkin recruitment due to deficiency in 
mitochondrial fusion (Narendra et al., 2008). One recent study led by Dr. Richard Youle 
showed that PINK1 is adequate to recruit Parkin to any organelle in which PINK1 
accumulates, triggering autophagy for some of these organelles (Lazarou et al., 2012). 
This finding rules out the necessity of any particular protein on any organelle as a 
substrate for Parkin and PINK1. If none of proteins on the organelles can serve as the 
common substrates, it is interesting to elucidate whether the most abundant membrane 
molecule, i.e. lipid, could be the substrates. Indeed, a genome-wide RNAi screen revealed 
that sterol regulatory element binding transcription factor 1 (SREBF1), F-box and WD40 
domain protein 7 (FBXW7) are involved in the recruitment of Parkin to mitochondria. 
SREBF1 acts as a transcriptional activator required for lipid homeostasis. Ablation of 
Parkin translocation caused by loss of SREBF1 indicates that lipid is indispensable for 
the process (Ivatt et al., 2014). Moreover, an externalization of cardiolipin to the OMM 
triggered mitophagy. Blockage of cardiolipin synthesis or inhibiting cardiolipin from 
being targeted to the OMM compromised incorporation of mitochondria to 
autophagosomes (Chu et al., 2013). 
 
It is still inconclusive for the role of ubiquitination of VDAC1 in mitophagy. Our data 
clearly demonstrate that ubiquitination of VDAC1 is not necessary for either Parkin 
translocation or mitophagy. As mentioned earlier, depletion of all three VDACs abolishes 
Parkin recruitment, while replenishment of any VDAC members is adequate to rescue the 
phenotype, including VDAC2 which is not ubiquitinated during mitophagy (Sun et al., 
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2012). Therefore, it is understandable that ubiquitination of VDAC1 may not contribute 
to Parkin translocation. However, whether ubiquitination of VDAC1 has a role in 
autophagic removal of mitochondria is yet to be explored. I demonstrated that elimination 
of ubiquitination of VDAC1 had no effect on mitophagy. This could be explained by the 
presence of ubiquitination of other OMM proteins. Furthermore, ubiquitination of 
VDAC1 may contribute to mitophagy in other manner. For instance, VDAC1 has been 
reported to be involved in apoptosis (Shoshan-Barmatz et al., 2010). Ubiquitination of 
VDAC1 may suppress apoptosis and ensure the execution of mitophagy without 
triggering apoptosis. In addition, the phosphorylation of Parkin (Kondapalli et al., 2012) 
and other possible substrates (Chen and Dorn, 2013; Koyano et al., 2014) of PINK1 has 
been intensively studied. However, the role of ubiquitination of these molecules remains 
largely unknown. Upon CCCP treatment, Parkin mediated broad ubiquitination of the 
OMM proteins. However, the precise roles of ubiquitination of each protein are yet to be 
studied. For instance, ubiquitination of which proteins is responsible for recruitment of 
autophagy machinery, while ubiquitination of which proteins facilitates their proteasomal 
degradation. Another interesting substrate of Parkin-mediated ubiquitination is Parkin 
itself. The ubiquitination of Parkin has been demonstrated to be involved in its 
proteasome-mediated degradation (Rakovic et al., 2013). However, it remains to be 
investigated that whether ubiquitination of Parkin is necessary for its activation or 
translocation to mitochondria.  
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4.4 Future prospect 
We have demonstrated that ROS play an important role in mitophagy. We postulate that 
ROS may fulfill its function in mitophagy through activating PINK1 or modifying other 
OMM proteins. To test if excessive ROS is responsible for the activation of PINK1, in 
vitro phosphorylation assay should be performed to examine whether ROS-treated 
PINK1 has a higher kinase activity compared to that in the control treatment. In this assay, 
both PINK1 and other PINK1 substrates, such as MFN2 and ubiquitin can be utilized as a 
substrate to show the activity of PINK1. On the other hand, to clarify if post-translational 
modification of other OMM proteins by ROS is important for Parkin translocation, a 
similar strategy of proteomics as the one used by Dr. Richard Youle’s group can be 
adopted (Kane et al., 2014). ROS production can be stimulated by CCCP treatment or 
VDAC1 overexpression. The OMM proteins are released from isolated mitochondria by 
trypsin digestion. Subsequently, mass spectrometry can be employed to analyze the 
digested peptides in an attempt to pinpoint the modifications caused by ROS production 
compared with the mitochondria extracted from cells without treatment of CCCP or 
VDAC1 overexpression. If we are able to map the changes on the mitochondria, depletion 
of the proteins which harbor the modification or even replacement of particular amino 
acids can be carried out to examine the effects on Parkin translocation. The protein or the 
amino acid which affects Parkin translocation should be a good candidate as a target of 
ROS on the mitochondria. The major possible problem for the search of ROS-mediated 
modification on the mitochondria is that ROS may cause a variety of changes on the 
mitochondria, while only one or two among them are responsible for Parkin translocation. 
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Therefore, the screening might be futile. It is also possible that the amino acid residues 
mutated in the study might affect Parkin translocation by other mechanism rather than 
ROS-induced modification, unless an in vitro assay could show that supplement of 
ROS-modified protein or peptide on mitochondria is sufficient for Parkin recruitment.  
 
In addition, an in vitro autophagy assay may help to answer the question that whether 
ubiquitination of VDAC1 has a role in mitophagy. Purified ubiquitinated VDAC1, 
VDAC1 without ubiquitination or 6A mutant of VDAC1 can be imported to mitochondria. 
Subsequently, we can check if the presence of these VDAC1 leads to any difference in 
convergence of autophagy machinery to mitochondria. If ubiquitination of VDAC1 
promotes mitophagy, the necessary mitophagy machinery could be isolated by 
immunoprecipitation with ubiquitinated VDAC1 and their roles in mitophagy could be 
further dissected in the future.   
 
Although we have established the importance of ROS in mitophagy, the detailed 
mechanism by which ROS drive mitophagy forward is yet to be investigated. It would 
also be interesting to explore the precise role of ubiquitination of VDAC1 in mitophagy. 
A better understanding on the roles of ROS and ubiquitination of VDAC1 in the process 
of mitophagy would help in utilizing mitophagy to treat neurodegenerative diseases.  
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Chapter 5 Conclusion 
PD is a devastating neurodegenerative disease with its pathogenesis largely unknown. 
Recently, it has been revealed that dysfunctional mitophagy is involved in PD, as Parkin 
and PINK1, the protein products of two genes related to familial PD, mediate 
autophagic clearance of damaged mitochondria. However, the regulation of mitophagy, 
especially how Parkin is recruited to mitochondria in a PINK1-dependent manner, 
remains enigmatic. It has been known that PINK1 accumulates on the outer membrane 
of the damaged mitochondria to recruit Parkin, eventually triggering mitophagy. In my 
study, I show that the accumulation of PINK1 on mitochondria is neither necessary nor 
sufficient for Parkin translocation to mitochondria. Our data also show that inefficacy of 
ROS scavenger results in its failure to reverse CCCP-induced Parkin translocation. We 
successfully inhibited Parkin translocation to mitochondria by either manipulating the 
dosage of CCCP or combining ROS scavengers. Moreover, PINK1-dependent Parkin 
translocation to mitochondria induced by VDAC1 overexpression could also be 
reversed by the combinatorial treatment of ROS scavengers. In addition, I mutated 
serine/threonine in VDAC1 to alanine and found a total of six mutations significantly 
affected its ubiquitination mediated by Parkin, though the precise role of ubiquitination of 
VDAC1 in mitophagy is yet to be clarified. 
 
Thus, our data highlight the importance of the presence rather than the accumulation of 
PINK1 in Parkin recruitment to mitochondria. PINK1 is indispensable for Parkin 
translocation, while the accumulation of PINK1 only facilitates the process. Our 
Chapter 5 Conclusion 
134 
 
findings suggest that activation of PINK1 may be more important for Parkin 
translocation to mitochondria than its accumulation. ROS are promising candidates as 
activator of PINK1, probably by promoting its autophosphorylation. Therefore, our 
study proposes ROS to be the initiative force to trigger the cascade of mitophagy, filling 
the gap of the model for PINK1-dependent Parkin translocation to mitochondria.  
 
My thesis also accentuates the necessity of fine-tuning ROS during mitophagy. ROS 
have been demonstrated to bring about devastating consequences for cellular health, 
especially in neurodegenerative diseases. However, to our knowledge, our data show for 
the first time that ROS are able to act as a signal to initiate mitophagy, thereby 
maintaining the homeostasis of cell. Furthermore, the discovery of this study conveys 
significant impact to pharmaceutical industry. Specifically, cautions should be taken 
when ROS scavengers are proposed to be utilized to fight against neurodegenerative 
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